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Zusammenfassung
Diese Arbeit besteht aus zwei Teilen, in denen strukturelle Aspekte verschiede-
ner Mechanismen der Translationskontrolle untersucht werden.
Das erste Kapitel untersucht den Mechanismus zur Aufhebung der Blockade
von Ribosomen (Ribosom stalling). Polyprolin-Abfolgen führen häufig zur Block-
ade des Ribosoms, die aufgehoben werden muss, um die mRNA translatieren
zu können. In Bakterien erfolgt dies durch den Elongationsfaktor P (Elongation
factor P (EF-P). EF-P wird durch verschiedene posttranslationale Modifikatio-
nen (PTMs) einer positiv geladenen Aminosäure aktiviert. Eine solche PTM ist
die Argininglycosylierung, die in etwa 10 % all Bakterienarten, darunter einigen
gefährlichen Pathogenen (z.B. Pseudomonas aeruginosa) konserviert ist. Arginin
wird dabei durch die Glycosyltransferase EarP mit Rhamnose verbunden. Beein-
trächtigung der Glycosylierung vermindert die Pathognität der Bakterien. EarP
ist jedoch bislang kaum charakterisiert, da es der erste dokumentierte Fall von
N-Glycosylierung eines Arginins in Prokaryoten ist. Daher wurde der Mechanis-
mus der EF-P rhamnosylierung durch EarP mit Hilfe von Kernspinresonanzspek-
troskopie, Röntgenstrukturanalyse und verschiedene biochemische Experimente
in vivo und in vitro untersucht. Die Struktur von EarP mit seinem Substrat dTDP-
Rhamnose wurde bestimmt und beleuchtet zusammen mit den in-vivo und in-
vitro Experimenten den wahrscheinlichen Mechanismus der EarP Rhamnosyla-
tion. Dies legt die Basis für die gezielte Entwicklung neuer Antibiotika.
Das zweite Kapitel behandelt die Hemmung der Translation der hunchback-
mRNA (hb). Die hb mRNA bildet während der Embryonalentwicklung der
Fruchtfliege Drosophila einen Proteingradienten aus, der zur Ausbildung der
Anterior-Posterior-Achse führt. Dieser Gradient entsteht durch die Unterdrück-
ung der mRNA durch einen Komplex aus drei Proteinen – Pumilio (Pum), Nanos
and Brain tumor (Brat). Die Expression von Nanos in einem Gradienten mit
entgegengesetzter Orientierung zum Hunchback-Gradienten definiert hierbei die
räumliche Orientierung. Die Expression der RNA-bindenden Proteine Pum und
Brat, die die hb-mRNA spezifisch erkennen, ist hingegen gleichförmig. Sowohl die
Struktur des an die hb mRNA gebundenen Brats als auch des Pum/Nanos/hb-
mRNA-Komplexes ist bekannt. Es ist jedoch bislangunklar, wie diese drei Proteine
zusammen auf der RNA angeordnet sind und ob sie strukturell und funktional
direkt verbunden sind. Ein Modell des Komplexes wurde anhand von Daten
aus Röntgen- und Neutronenkleinwinkelstreuungsexperimente und Abstandsin-
formationen aus der Massenspektrometrie des quervernetzten Komplexes (Cross-
linking mass spectrometry) erstellt. Diese Daten wurden vervollständigt und
bestätigt durch verschiedene in vitro assays, wie z.B. Affinitätselektrophorese oder
Isotherme Titrationskalorimetrie. Die Untersuchungen geben erste Einblicke in
die Struktur des Komplexes und ebnen den Weg für zukünftige Versuche zur
vollständigen Aufklärung der Struktur des Komplexes.
Summary
The thesis comprises twoparts investigating structural aspects of variousmech-
anisms of translational control.
The first chapter investigates a mechanism behind ribosome stalling allevia-
tion. Poly-proline stretches often induce ribosome stalling, which needs to be
alleviated to translate themRNA. In bacteria the ribosomes are rescued by Elonga-
tion Factor P (EF-P). EF-P is activated by diverse post-translational modifications
(PTMs) of a positively charged amino acid. Such PTM is the glycosylation of
arginine conserved in approximately 10% of all bacterial species including severe
pathogens (e.g. Pseudomonas aeruginosa). The arginine is glycosylated by a gly-
cosyltransferase EarP which attaches rhamnose to the arginine. Impairing the
glycosylation reduces the pathogenicity of the bacteria. However, EarP is an un-
characterized glycosyltranferase as it is only the first documented case of arginine
N-glycosylation in prokaryotes. Hence, the mechanism of EF-P rhamnosylation
by EarP was investigated using nuclear magnetic resonance spectroscopy, X-ray
crystallography and various in vivo and in vitro assays. The atomic structure of
EarP with its substrate dTDP-rhamnose was solved and the in vivo and in vitro
assays together with subsequent studies elucidate the putativemechanism of EarP
rhamnosylation thus providing basis for targeted antibiotic drug design.
The second chapter investigates the translational suppression of the hunchback
(hb)mRNA. The hbmRNA forms during Drosophila development a protein gradi-
ent governing the anterior-posterior body axis formation. The Hunchback protein
gradient results from the suppression of hb mRNA at posterior by a complex of
three proteins – Pumilio (Pum), Nanos and Brain tumor (Brat). Nanos, expressed
in an opposing gradient to Hunchback, provides spatial information. Uniformly
expressed Pum and Brat are RNA binding proteins that specifically recognize the
hb mRNA. The structure of Brat bound to the hb mRNA, and the structure the
complex of Pum and Nanos bound to the hbmRNA have been previously solved.
However, it remains unclear how exactly these three proteins assemble on the hb
mRNA together, and if they are structurally and functional directly linked. The
complex was investigated using modelling based on small-angle X-ray and neu-
tron scattering data combined with additional restraints from cross-linking/mass
spectrometry. The data were further complemented and validated by various
in vitro assays such as electrophoretic mobility shift assays and isothermal titra-
tion calorimetry. The investigation provides initial insights about the complex and
paves theway for future approaches to fully elucidate the structure of the complex.
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General Introduction
The most fundamental molecular process to create life is the process of gene ex-
pression. The genetic information of an organism during this process gradually
manifests into biological function. First, the DNA is transcribed into RNA, which
is in turn translated into a protein8. It is tightly controlled by several mechanisms
which are in sum referred to as the regulation of gene expression. Regulation is
possible at any step, so it goes without saying that regulation of gene expression
spans a vast plethora of processes. The true importance of those processes regulat-
ing gene expression is revealed upon examining genome sizes across species9. The
increase in functional complexity of organisms does not necessarily stem from an
increase in genome size. It must therefore originate in an increase of complexity
with which the genomes are expressed. This requires the universal process of
gene expression to be plastic. The plasticity of gene expression lies in its regula-
tion. Furthermore, regulation of gene expression allows the organisms to adapt
phenotypically to changes in the environment.
Regulation happens both at the level of transcription of a DNA into an RNA
and the level of translation of the RNA into a protein. In general, transcription
regulation seems to be less conserved and largely associated with phenotypical
adaptation and diversity, while translation regulation is more conserved and is
postulated to be a buffer10. As messenger RNAs (mRNAs) have a generally long
half-life, translation regulation is thought to provide fast response to maintain
homeostasis. Translation regulation is then crucial for dynamic gene expression
in processes common to all organisms such as cell cycle, metabolism, growth and
development.
The key mechanisms of translation regulation are the best demonstrated in the
context of translation11. Translation consists of four phases: initiation, elonga-
tion, termination and recycling12. Some general mechanisms are shared between
eukaryotes and prokaryotes, but there are also substantial differences. The most
obvious difference is that in prokaryotes due to the lack of the nuclear membrane,
translation is physically coupled to transcription. As a consequence, bacterial mR-
NAs are often polycistronic (code multiple proteins in a single molecule) and have
a rather simple structure. The eukaryotic mRNAs, on the other hand, need to be
exported to the cytoplasm, so they are equipped with a m7G-cap at the 5’ end and
a polyA tail at the 3’ end.
The initiation of translation starts with the binding of the small ribosomal
subunit (30S or 40S in prokaryotes or eukaryotes, respectively) to the mRNA and
of the initiator transfer RNA (tRNAi) to a methionine start codon. The binding
– 1 –
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of both the tRNA and the small ribosomal subunit to the mRNA is promoted by
numerous initiation factors. In the second step of the initiation the complex of the
small ribosomal subunit, the tRNA and the initiation factors on the mRNA recruit
the large ribosomal subunit (60S or 70S in prokaryotes or eukaryotes, respectively).
As a result, a fully formed ribosome is assembled on themRNAwith the first tRNA
ready in the peptidyl site (P site).
This can be already controlled by preventing the assembly of the ribosome
on the mRNA in two general manners - either by affecting the initiation factors
or ribosomal subunits or by targeting the mRNA itself by the means of RNA-
binding proteins or microRNAs13,14. The first way provides an opportunity to
control translation globally, whereas the second one has consequences only for the
synthesis of a specific protein. A prime example of the regulation of translation
by RNA-binding proteins is the suppression of Hunchback mRNA translation in
Drosophila development, which is the central topic of chapter 2.
During elongation, the ribosome proceeds to synthesize the protein from the
template mRNA. It starts with an amino acid-charged tRNA binding its comple-
mentary codon presented in the aminoacyl site (A site) of the ribosome. Then the
P site amino acid is transferred to the A site by forming a peptide bond with the
previously arrived amino acid. The discharged P site tRNA then translocates to
the exit site (E site) of the ribosome and the A site tRNA translocates to the P site.
Eventually, the E site tRNA is released from the ribosome. This cycle then repeats
itself to synthesize the new protein.
Generally, elongation is thought to occur at its maximum rate and initiation
is the rate limiting step in translation. Therefore, initiation is the logical target
for efficient translation regulation, especially considering that it is the step when
the least has been invested so far. However, regulation of elongation contributes
valuably to dynamic regulation of gene expression. The rate of elongation is
controlled by the sequence and structure of the mRNA itself and slowing the
translating ribosome down provides an opportunity to increase the variety of
products. For example, stalled ribosomes can alter the structure of the mRNA
downstream, thus allowing synthesis of another protein15. It also provides an
opportunity to re-program the translation, for example by shifting the ribosome
a base upstream or downstream to access an alternative reading frame on the
same mRNA16. While the first is an example of regulation that plays only a minor
role, the second example is an extremely important feature that allows viruses to
have particularly compact genomes17. A great illustrative example of how simply
mRNAs control the rate of the elogantion is proline translation18. Prolines are due
to their chemical nature incorporated into the nascent peptide chain significantly
slower than other amino acids. Consecutive stretches of prolines can then easily
slow down and stall the ribosome. The mechanism behind the alleviation of this
poly-proline induced stalling in bacteria is the central topic of chapter 1.
When a stop codon reaches the A site of the translating ribosome the termina-
tion of translation is triggered. The termination is orchestrated by a set of factors,
which first stimulate the cleavage of the peptidyl-tRNA bond causing the release
of the peptide and then stimulate the dissociation of the ribosome into subunits.
General Introduction 3
Eventually, additional factors dissociate the tRNA and togetherwith the ribosomal
subunits recycle it for another round of translation. The stop codon itself provides
another vital opportunity to increase the variety of translation products. The two
main mechanisms to control termination of translation involve either suppressing
the stop codon by misreading it by an amino acid-charged tRNA19 and read-
through of the stop codon by erroneously incorporating another amino acid20.
Both mechanisms result in continued elongation thus synthesizing an alternative
gene product.
This illustrates how common and how important regulation of translation is
in context of regulation of gene expression. In this work two mechanisms behind
regulation of translation were investigated in details.

Chapter 1
Rhamnosylation of Elongation factor
P in alleviation of ribosome stalling
1.1 Introduction
1.1.1 Translation proceeds at non-uniform rates
Translation elongation can principally only be used for regulation if substantial
control of the rate of elongation is possible. Indeed, the first evidence that trans-
lation does not proceed in constant rate has been provided more than 30 years
ago21,22. Possibly any molecular biologist who ever expressed a protein recom-
binantly must be aware of this, because the rate of elongation was first linked to
the frequency of synonymous codon occurrence - a fact commonly exploited to
optimize yields of recombinant proteins23,24.
However, it is only with the revival of ribosome profiling that the non-uniform
rate of translation emerged in its full scale25. This prompted the opening of new
avenues to study themechanisms that control the rate of elongation and their roles
in translation regulation26. Since then evidence emerged that the rate of elongation
does not depend only on codon decoding, but also on the amino acid incorporated
into the nascent peptide chain18,27. Proline was shown to be the amino acid, which
is incorporated into the peptide chain particularly slowly. This was suggested to
be due to its cyclic chemical nature. In parallel, stretches of consecutive prolines
(poly-proline stretches) were found in a large portion of peptides inducing stalling
in vivo15,28. In bacteria, proteins with poly-proline stretches amount to about 10%
of the genome29,30. To control the poly-proline induced stalling there must also
be a mechanism to alleviate it. For that all domains of life use a translation factor
called Elogantion Factor P (EF-P) in bacteria, or Initiation Factor 5A (IF-5A) in
eukaryotes and archea31–34.
1.1.2 Consecutive prolines induce stalling
The elongation is fairly universal across organisms35. A productive elongation
cycle starts with the peptidyl-tRNA bound in the P site of the ribosome. The
– 5 –
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unoccupied A site is then bound by a new acetyl-tRNA in a complex with GTP
and EF-Tu or EF1A (in prokaryotes or eukaryotes, respectively). The tRNA then
base-pairs with the mRNA codon in the A site to decode the codon. The A site
tRNA amino acid is then positioned in Peptidyl Transfer Centre (PTC) of the
ribosome in vicinity of the nascent peptide chain bound to the tRNA in the P site.
A new peptide bond is then formed transferring the nascent peptide chain to the A
site tRNA and leaving the P site tRNA deacetylated. The tRNAs (and the mRNA)
are then translocated to leave the A site vacant with the use of GTP by EFG or
EF2 (in bacteria or eukaryotes, respectively). The deacetylated tRNA is now in the
E site and leaves the ribosome. The peptidyl-tRNA is back to the P site with the
nascent peptide chain one amino acid longer and ready to initiate another round
of elongation.
When poly-proline stretches are translated, the peptide bond formation seems
to be the problem causing ribosome stalling. This is thought to be due to the
observed tendency of Pro-Pro dipeptides to adopt a conformation which would
cause the nascent peptide to clash with the exit tunnel of the ribosome36. The
nascent poly-proline peptide would be only accommodated by destabilizing the
P site peptidyl-tRNA, which in turn would prevent the accommodation of the A
site acetyl-tRNA. That causes the ribosome to stall and requires EF-P (IF-5A) to
alleviate the stalling.
stalled ribosome alleviation translation
EF-P
PTM
E P A E P A
proline
tRNA
mRNA
ribosome
Figure 1.1 Alleviation of ribosome stalling by Elongation Factor P (EF-P). Translation of poly-
proline stretches induces ribosome stalling. The stalling is alleviated by EF-P, which is activated
by a post-translational modification (PTM) of a positively charged residue in loop at the tip of the
N-terminal domain. EF-P binds between the E and P sites of the ribosome, where the modified
residue reaches near the Peptidyl Transfer Centre and stimulates peptide bond formation thus
alleviating the stalling. The translation resumes saving the nascent peptide chain, the mRNA and
the assembled ribosome.
1.1.3 The Elongation Factor P alleviates stalling
Generally, EF-P and IF-5A act in a similarway33,36–38. Both factors bind between the
P and the E site of the ribosome and extend a loop towards the acceptor stem of the
tRNA in the vicinity of PTC. The EF-P (IF-5A) loop contains a conserved positively
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charged residue that for full activity of the factor needs to be post-translationally
modified. This protruding modified residue interacts with the CCA end of the
tRNAforcinga structural rearrangement that alters the conformationof thenascent
peptide chain. The conformational change of the nascent peptide chain leads to
a favourable substrate geometry and the peptide bond may form. The positively
charged residue reaching the acceptor stem was found to be modified by a variety
of post-translational modifications (PTMs)1,31,33,39–41.
1.1.4 Post-translational modifications of the Elongation Factor P
EF-P is an L-shaped molecule consisting of three domains generally resembling
the shape of a tRNA42–44(unpublished, PDBID 1YBY). The first, N-terminal domain
folds into a β-barrel comprising six β-strands termed KOW-like domain, which
is homologous to SH3-like domain family typical for transcription factors. The
second common domain adopts the OB-fold, which is typically a five stranded
β-barrel capped by a helix between strand 3 and 4 and is commonly seen binding
nucleic acids. The third, C-terminal domain also adopts an OB-fold. The N-
terminal KOW-like domain is the domain that harbours the positively charged
residue needed for efficient stalling alleviation. The residue is located in a loop
between strands β3 and β4. In IF-5A the residues is a conserved lysine. However,
the lysine is conserved only in about 26% of bacteria1. In about 10% of all bacteria
species the conserved lysine is replaced by an arginine. This lysine or arginine is
post-translationally modified by diverse pathways.
The lysine of IF-5A was shown to be modified by hypusination45. This is
a modification of lysine in a two step reaction. First, deoxyhypusine synthase
modifies the lysine using spermidine as a substrate. The resulting deoxyhypusine
is then hydroxylated by deoxyhypusine hydroxylase to form hypusine. The lysine
of EF-P was so far found to undergo two different modifications. The first is a
three-step β-lysination and hydroxlation of the lysine. First, the aminomutase
EpmB converts an α-lysine into (R)-β-lysine46. EmpA then uses (R)-β-lysine to
acetylate the EF-P lysine47,48. Eventually, the β-lysinated lysine is hydroxylated
by EmpC49. Alternatively, the lysine of EF-P is modified by 5-aminopentanol41.
However, the molecular pathway of this modification remains unclear.
The last documented modification system activates the EF-P with a conserved
arginine1. The arginine is glycosylated by an enzyme termed EarP using dTDP-
rhamnose as the substrate. This pathway is conserved in about 10% of all bacteria
including some severe pathogens such as P. aeruginosa. Moreover, pathogenicity in
P. aeruginosawas shown todependon the EF-P rhamnosylationpathway. However,
arginine glycosylation was only reported in a very few cases50,51 and at the start
of this work, no molecular details of the catalysis were known. Therefore, we
investigated the chemistry of EF-P rhamnosylation by EarP.
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1.2 Aims
To shed light into themechanism of EF-P rhamnosylation by EarP this study aimed
to investigate the following aspects of the rhamnosylation:
• The interaction of EF-P with EarP.
• The configuration of the anomeric carbon of the rhamnose throughout the
reaction.
• The interaction of EarP and dTDP-rhamnose.
• The structure of EarP.
• The structure of a complex of EarP with dTDP-rhamnose and/or EF-P.
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1.3 Results
1.3.1 EarP interacts with the N-terminal domain of Elongation
factor P
The investigation of EF-P rhamnosylation was initiated by studying the unmodi-
fied and rhamnosylated EF-P by nuclear magnetic resonance (NMR) spectroscopy.
First, the resonance frequencies of both versions of EF-P were assigned using the
standard triple resonance approach52 yielding assignment of 98% of the back-
bone resonances. Then, the interaction of EF-P with EarP was studied by NMR
titrations. Both versions of EF-P were expressed 15N labelled, purified and then
titrated by unlabelled EarP. The titrationswere carried out step-wise until a 1:2 (EF-
P:EarP) molar ratio. Unmodified and rhamnosylated EF-P over the course of the
titration undergo significant chemical shift perturbations (Figure 1.2). Morever, a
number of peaks show substantial line broadening including the rhamnosylation
target residue R32 and its surrounding residues, which broaden beyond the limit
of detection. This indicates that EarP indeed binds EF-P in vitro. The changes
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Figure 1.2 The interaction of Elongation Factor P (EF-P)with EarP. (a)Nuclearmagnetic resonance
spectroscopy titration of EF-P byEarP.UnmodifiedEF-Pwas titrated byEarP to 1:2 EF-P:EarPmolar
ratio and the progress of the titration was monitored by recording a 15N HSQC spectrum at each
step of the titration. The recorded spectra are displayed overlaid with colour coding for respective
titration steps indicated in the upper left corner. Examples of peaks undergoing high chemical
shift perturbations (CSP) or severe line-broadening are shown by labels indicating the assignment
of a given peak. (b)CSPs of unmodified and rhamnosylated EF-P titrated by EarP. Unmodified and
rhamnosylated EF-P were titrated by EarP, the CSPs were calculated according to the Equation 1.1
and plotted against residue number back to back with the CSP unmodified EF-P oriented upwards
and the CSP of the rhamnosylated oriented downwards. Full lines indicate mean CSP, dashed
lines indicate mean CSP plus standard deviation and residues with CSPs higher than median plus
standard deviation are shown in a brighter shade of respective colours. The arrowwith the label in
the plot indicated the position of the rhamnosylated residue R32. Domain organization is outlined
above the plot. The figure is adapted from Krafczyk et al. 2 .
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of chemical shifts were then for both versions of EF-P assesed quantitatively by
calculating the chemical shift perturbations (CSPs, Figure 1.2b). The assessment
reveals that the CSPs are overall weaker for the rhamnosylated EF-P than for the
unmodified EF-P, which indicate that EF-P interacts stronger with EarP unmodi-
fied. This is not surprising considering that modified EF-P is the substrate of EarP
and the rhamnosylated EF-P is the product. The highest CSP are located mostly
in the N-terminal KOW-like domain as expected considering that it is the site of
the rhamnosylated R32. However, almost no above average CSPs were observed
in the central and C-terminal EF-P domain. The eukaryotic and archeal homolog
of EF-P, IF-5A, interestingly misses the C-terminal domain completely. EF-P was
then truncated by removing either the C-terminal domain or both the C-terminal
and the central domain and tested for rhamnosylation2. The EF-P comprising only
the N-terminal domain was still found rhamnosylated.
1.3.2 EarP is an inverting glycosyltransferase
The attached rhamnose moiety was then investigated in detail. First, the sugar
ring was assigned using 13C edited NOESY-HSQC spectrum (Figure 1.3a). The
main parameter of interest was then the configuration of the anomeric carbon of
the sugar ring. The substrate sugar derivative EarP uses is dTDP-β-L-rhamnose.
Determining the anomeric configuration of the attached sugar reveals whether it
was retained or inverted throughout the reaction. The inversion or retention of
the anomeric configuration is a criteria of classification for glycosyltransferases as
relates to the chemistry the enzyme uses53.
Two approacheswere taken in order to reveal the anomeric configuration of the
bound rhamnose. One bond scalar coupling between the H1’ and C1’ (1JH1′,C1′)
was reported to be indicative of the anomeric configuration in sugars54. For an
α-L-rhamnose values around 170 Hz are expected, whereas for a β-L-rhamnose
the coupling should only be 160 Hz. This coupling is normally of no importance
and would increase the difficulty of the interpretation of a spectrum, so it is com-
monly suppressed by decoupling. Therefore, 13C-HSQC spectra were measured
without decoupling in order to measure the scalar coupling. Three variants of the
experiment were measured to ascertain the value - one with the coupling resolved
in the direct dimension and two with the coupling resolved in the 13C dimension,
onewith a large number of points for better resolution and the otherwith a smaller
number of points to not resolve C-C coupling. The 1JH1′,C1′ couplingwasmeasured
to be 167 Hz.
α-L-rhamnose and β-L-rhamnose also differ substantially in the H1’-H5’ dis-
tances. In α-L-rhamnose these hydrogens are 3.5 Å apart, whereas in β-L-
rhamnose the distance is only 2.4 Å. The distance can be determinend experi-
mentally from the 13C edited NOESY-HSQC spectrum used for the assignment.
The NOESY spectrum of rhamnosylated EF-P lacks a cross-peak between the H1’
and the H5’ indicating the longer of the two distances.
Collectively these data show that the attached rhamnose has α configuration
on the anomeric carbon. The substrate has β configuration, so this classified EarP
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Figure 1.3 The anomeric configuration of the rhamnose attached to Elongation Factor P (EF-P).
(a) The assignment of the rhamnose attached to EF-P. The sugar resonance region of 13C HSQC
of rhamnosylated EF-P is shown with labels indicating the assignment of the sugar ring. The
rhamnose moiety was assigned using a 13C edited NOESY-HSQC spectrum. (b) Stick represen-
tation of α-L and β-L-rhamnose with typical values of 1JH1′,C1′ scalar coupling54 and H1’ to H5’
distance, and a display of the H1’,C1’ peak of the 13C-HSQC spectrum without decoupling with
the measured value of the scalar coupling. (c) Strips of the 13C edited NOESY-HSQC spectrum.
The green box indicates the lack of the observableNOE betweenH1’ andH5’. The figure is adapted
from Li et al. 55
as an inverting glycosyltransferase55,56.
1.3.3 Two opposing Rossman fold domains form EarP
The structure of Earp was then investigated to gain further insights into the rham-
nosylation EF-P by EarP. First, EarP was studied by NMR. EarP is in its full-length
a 43 kDa protein and is beyond the size limit of structures typically solved by
NMR. Unfortunately, soluble truncation of EarP could not be found, so the full
length proteinwas studied byNMR.Deuteration of EarP and the use of transverse-
relaxation optimizedNMRspectroscopy (TROSY)was required, but eventually led
to the assignment of 62% of EarP backbone resonances. 2H,15N-labelled EarP was
then titrated by dTDP-rhamnose to 1:5 EarP:dTDP-rhamnose molar ratio. The
titration shows that EarP undergoes chemical shift perturbations (Supplementary
Figure 1a). While this clearly confirms that EarP binds dTDP-rhamnose in vitro,
further quantification of the changes by CSP were not particularly informative as
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structural information is needed to extract information about the exact interaction
surface (Supplementary Figure 1b). The structure of EarP was then investigated
by X-ray crystallography.
EarP was co-crystallized with dTDP-rhamnose. The crystallization conditions
were optimized to 0.2 M ammonium acetate, 0.1 M bis-Tris, 27% (w/v) PEG 3350,
pH 6.0 at 4◦C. The crystals provided several full datasets up to 2.3 Å resolution.
However, no suitable model could be found for molecular replacement. To ex-
perimentally determine the phases EarP was then crystallized again labelled with
seleno-methionine (SeMet). The phases were then solved on 3 Å dataset with the
anomalous signal extending to 3.4 Å by single-wavelength anomalous dispersion
(SAD). The native dataset was then used to extend the resolution to 2.3 Å.
The electron density reveals a well-defined C-terminal domain and partially
an N-terminal domain. A weak electron density for the N-terminal domain can
be observed, however it is not sufficient for building a model unambiguously.
The resulting structure then shows an R-free value of 0.35, which is unusually
higher than expected at this resolution . Extensive data quality control was then
carried out to find the cause of the bad quality of the electron density for the
N-terminal domain. The space group was determined to be I4. To check if it
is indeed the correct space group the data were processed again in C2 and P1
space group. This would reveal if non-crystallographic symmetry is mistaken for
crystallography symmetry as C2 and P1 are subgroups of I4 with more molecules
in the asymmetric unit. However, the electron density did not improve when the
data were processed as C2 or P1 space groups. Furthemore the data do not show
any signs of anisotropy or twinning. Crystal slippage or radiation damage is not
visible during XDS processing. EarP has 6 methionines including the initiatior
methionine, which is expected to be disordered as a part of the terminus. Overall
5 SeMet were expected during substructure determination. It is possible to indeed
locate 5 selenium atoms, but only the 3 present in the C-terminal domain showed
full occupancy. The 2 selenium atoms in the N-terminal domain only have 0.5
occupancy. This might arise from conformational heterogeneity of EarP across
different unit cells. Fortunately, the dTDP-rhamnose binding site is located in the
part of the structure with the good quality of electron density, so the structure still
revealed many important insights about EarP.
EarP comprises two Rossman fold domains (Figure 1.4). The Rossman fold
is a super-secondary structure motif characteristic for the alternation of α-helices
and β-strands throughout the sequence of the protein. These than arrange so that
the β-strands form a central sheet and the α-helices alternate on either side of the
sheet. The C-terminal domain of EarP is defined, so the topology of the fold is
clearly visible. It features a central β-sheet consisting of four parallel β-strands
β8, β9, β11 and β8 and one anti-parallel β-strand β10. The central sheet is then
surrounded by α-helices α7-α13 and the C andN-terminal domains are connected
by two minor α-helices α5 and α6.
The topology of the N-terminal domain was not completely clear from the
structure. Fortunately, secondary structure can be easily determined from NMR
chemical shifts, so EarP assignments were then used to calculate the secondary
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Figure 1.4 The structure of EarP. (a) The structure of EarP determined by X-ray crystallography at
2.3Å resolution. The structure reveals two Rossman fold domains as indicated above the structure.
(b)The topologydiagramof EarP. The topology of EarP is shownwith arrows representing β-sheets
and bars representing α-helices. The diagram is divided into the domains which are indicated
above. The blank dashed elements indicate secondary structure elements inferred from chemical
shifts and homology modeling2. (b) Secondary structure propensity of EarP determined from
NMR chemical shifts. Secondary structure propensity of EarP was calculated from Cα, Cβ and
backbone N and H secondary chemical shifts using TALOS+57. The plot shows the propensity of
each residue to form either β-sheet (pointing upwards) or α-helix (pointing downwards). Zero
values either indicate the propensity to form a random coil or lack of information. Domain
boundaries are indicated above the plot. α-helices are coloured in pale green and β-sheets are
colour in beige. The figure is adapted from Krafczyk et al. 2 .
structurepropensity of EarP (Figure 1.4c). This informationwas thenused together
with homology modelling2 to predict the full topology of the N-terminal domain
(Figure 1.4b). The N-terminal domain was predicted to compromise a central β-
sheet of β-strands β1 to β7 surrounded by α-helices α1 to α4 and α14, which was
visible in the crystal structure to reach back from the C-terminal domain making
the N-terminal domain the one to actually harbor both termini.
1.3.4 The inter-domain cleft harbours dTDP-Rhamnose
EarP was crystallized with an excess of dTDP-rhamnose, so the electron den-
sity was inspected for a presence of the small molecule. This indeed revealed
a molecule of dTDP-rhamnose bound in pocket in the inter-domain cleft (Fig-
ure 1.5). Detailed inspection reveals a network of interactions between EarP and
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Figure 1.5 The interaction of rhamnose and EarP. (a) and (b) The crystal structure of EarP with
bound dTDP-rhamnose. EarP is displayed in grey surface representation, the molecule of dTDP-
rhamnose is shown in magenta stick representation. The black square in panel (b) outlines the
zoomed in area in panel (c). (c) Molecular details of dTDP-rhamnose recognition by EarP. The
residues of EarP interacting with dTDP-Rhamnose shown in cyan sticks with labels. Dashed lines
indicate hydrogen bonds. (d) In vitro and in vivo validation of EarP-dTDP-rhamnose interaction. A
list of EarP point mutations was assayed for rhamnosylation activity in vitro and in vivo. The upper
part of the panel shows a diagram of the in vivo assay - β-galactoside reporter gene is fused to
the PcadAB promoter, which is activated under pH stress by CadC. The CadC translation depends
directly on EF-P activity as CadC contains a poly-proline stretch32. The results of the in vivo assay
are given in the second column of the table. The in vitro activity was measured by incubating
constant amounts of unmodified EF-P and EarP with increasing amounts of dTDP-rhamnose. EF-
P rhamnosylation was then quantified by a western blot using antibody against the rhamnosylated
arginine55. The results of the in vitro assays are in the third and the fourth column. Km is the
Michaelis-Menten constant, kcat is the turnover number. The in vivo assay diagram was kindly
provided by Dr. Lassak. The figure is partially adapted from Krafczyk et al. 2 .
dTDP-rhamnose (Figure 1.5c). First, the three aromatic residues F252, F191 and
F258 stack against the thymine of the nucleotidemoiety. TheV253 then via its back-
bone amide forms a water-mediated hydrogen bond with the O4 of thymine. The
side-chain of Q255 forms a hydrogen bond with the O3’ in a specific recognition
of the ring. Residues E273, D274 and S275 then with their backbone amid groups
form several hydrogen bonds with the first phosphate of the diphosphate. The
side-chains of R271 and Y193 then form hydrogen bonds with the second phos-
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phate. Interestingly, the nucleotide part forms all the contacts with the protein
and is buried in the binding site, whereas the rhamnose moiety does not contact
the protein at all and is completely solvent exposed. This was further confirmed
by saturation transfer difference (STD) NMR experiments, where only signal from
the dTDP moiety and not from rhamnose were observed2.
Based on these interactions several of the interacting residues of EarP were
mutated to alanines. Then, the activity of the mutated EarP was assayed both in
vivo and in vitro. The in vivo assay was a gene-reporter assay based on a previously
described EF-P dependent system using CadC (Figure 1.5d)32. CadC under pH
stress activates the PcadAB promoter. However, CadC contains a poly-proline
stretch and directly requires active EF-P for translation. In the assays, endogenous
EF-P and EarP are deleted and PcadAB promoter is fused to β-galactosidase reporter
gene. β-galactosidase is then used to evaluate the activity of exogenous mutated
EarP. The in vitro activity ofmutated EarPwas simply tested by incubating constant
amounts of EF-P and EarP with increasing amounts of dTDP-rhamnose , and
monitoring the level of rhamnosylation by western blot using antibody against
rhamnosylated arginine55. F191A, Y193A and R271A mutation showed a strong
effect on β-galactosidase activity in vivo, while the in vitro kinetics were worse for
the majority of mutated residues generally validating the structure.
1.3.5 The putative catalytic residues of EarP
The reaction mechanism of inverting glycosyltransferases is SN2-like direct dis-
placement reaction53. In such a reaction an acidic residue in the active side
of the glycosyltransferase (EarP) serves as a base deprotonating the nucleophile
side-chain of the acceptor (EF-P). The acceptor side-chain than displaces the nu-
cleotide resulting in glycosylation. In case of N-glycosylation the deprotonation
requires two acidic side-chains58. Therefore, sequence alignments of EarP or-
thologs were combined with details from the structure of EarP to find putative
catalytic residues2. This approach revealed three residues - D13, D17 and E273
(Figure 1.6a). Each of these is invariant in EarP and in vicinity of dTDP-rhamnose
binding site. D13, D17 and E273 were then mutated to alanines and the activity
of mutated EarP variants was assessed in vivo and in vitro as described above. In
all three cases the mutation abolishes the activity of EarP in vivo. Moreover, no
rhamnosylation could be detected in vitro whatsoever by EarP containing D13A,
D17A or E273A mutations (Figure 1.6b).
The mutations were then tested for dTDP-rhamnose and EF-P binding to see if
the loss of activity originates froma loss of bindingof either. The rhamnosebinding
of D13A and D17A variants was tested by performing NMR titrations as for the
wild-type(WT) EarP. In both cases similar chemical shift changes were observed
as for the WT EarP indicating the interaction is preserved in those mutants2.
Interestingly, the WT EarP titration shows chemical shift changes in a cluster
of residues including G16 and G19. These residues do not directly participate
in dTDP-rhamnose binding pocket, but are in the vicinity of D13 and D17 and
the binding pocket. That makes these residues valuable indicators of binding of
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Figure 1.6 The putative catalytic residues of EarP. (a) Molecular details of proposed putative
catalytic residues of EarP. The putative catalytic residues are shown in yellow sticks with labels,
the dTDP-rhamnose is shown in magenta sticks and EarP is shown in grey cartoon. EarP is an
inverting glycosyltransferase which employs SN2-like reaction mechanism, which requires nega-
tively charged catalytic residues to activate the receiving side-chain group53. Candidate residues
in EarP were identified by searching for conserved negatively charged residues in the vicinity of
the bound dTDP-rhamnose2. The three putative catalytic residues are invariant in all EarP or-
thologs. (b) In vitro and in vivo testing of the activity of alanine substitutes of the putative catalytic
residues. The results from the in vivo assay are in the second column, the results of the in vitro
assay are in the third and the fourth column. The assay followed the same principles as described
in Figure 1.5. The n.d. stands for not detectable. (c) Test of dTDP-rhamnnose binding by EarP with
alanine substitutions of the putative catalytic residues. NMR titrations of EarP variants were done
to verify dTDP-rhamnose binding of the EarP with alanine substitutions of the putative catalytic
residues. G16 and G19 are in direct vicinity of the D13 and D17 residues and in wild-type EarP
their chemical shifts change by the interaction with dTDP-rhamnose. Therefore these residues
were observed in the titrations of D13A and D17A as reporters of dTDP-rhamnose binding. The
figure shows a section of the 15NHSQC spectra containing the peaks of the G16 and G19 residues,
the full spectra are available in Krafczyk et al. 2 . Similar reporter was unavailable for E273 due
to missing assignment. Nevertheless dTDP-rhamnose binding was confirmed by STD NMR for
E273A EarP2. (c) Test of EF-P binding to EarP with alanine substitutions of the putative catalytic
residues. To test whether the alanine substitutions in EarP impair EF-P binding, bacterial two hy-
brid assay were performed59. The assay tests protein interactions in E. Coli by fusing the proteins
of interest to the domains of the adenylate cyclese toxin. Protein-protein interactions lead to the
reconstitution of the toxin and result in blue phenotype in the commercially supplied kit which
was used (Euromedex). The figure is partially adapted from Krafczyk et al. 2 .
dTDP-rhamnose in the correct site. This is particularly important as smallmolecule
ligands can often bind multiple sites on a single protein molecule. Observing the
G16 and G19 cluster during the NMR titration of D13A or D17A variants in both
cases reveals similar chemical shift changes as for the WT EarP (Figure 1.6c).
The D13A, D17A annd E273A EarP variants were then assayed for EF-P bind-
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ing using a bacterial two hybrid assay59. EarP and EF-P were expressed in E. Coli
fused to fragments of the adenylate cyclase toxin. Their interaction would lead to
the reconstitution of the toxin and result in blue phenotype in the commercially
supplied kit which was used. For all three EarP variants in the assay blue phe-
notype was observed showing that the D13A, D17A and E273A EarP variants still
bind EF-P (Figure 1.6d).
In conclusion, the residues D13, D17 and E273 are crucial for EarP glyco-
syltransferase activity, but are dispensable for EF-P or dTDP-rhamnose binding,
which identifies them as promising putative catalytic residues.
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1.4 Discussion
This study was quickly followed by more publication by others3,4. Together with
this structure of EarP from P. putida several additional structures were solved. The
structure of EarP fromN. meningitidiswas solved in the apo form, in complex with
dTDP-rhamnose and in complex with the N-terminal domain of EF-P and dTDP.
The structure of EarP from P. aeruginosa was solved in the apo form, in complex
with dTDP or dTDP-rhamnose and in complex with EF-P and dTDP. These are of
tremendous importance as they often fill the gaps in this study. Collectively, these
works paint a fairly detailed image of the mechanism of EF-P rhamnosylation by
EarP.
The full EarP structure is indeed very similar to the structure proposed here
except for some inaccuracies in the prediction of the N-terminal domain, which
could not be fully solved due to the poor electron density. The major inaccuracy
is that the central β-sheet consists of 8 β-strands instead of the 7 predicted here.
However, the C-terminal domain of the P. putida EarP presented here aligns very
well to the EarP from P. aeruginosa (0.6 Å RMSD)4.
dTDP-rhamnose binds EarP in the conserved binding pocket located in the
inter-domain cleft. The binding does not induce any large conformational changes
in any of the structures2–4. However, the loops in EarP forming the binding pocket
of dTDP-rhamnose seem to be disordered in the apo form and well resolved in the
bound form suggesting they are stabilized by the donor binding4. The interaction
with dTDP-rhamnose is very conserved and agrees well with the description here.
The base of the nucleotide resides in an aromatic pocket formed by three aromatic
residues, the O3’ of the deoxyribose is specifically recognized by a glutamine
side-chain and the diphosphate is stabilized by a network of backbone and side-
chain hydrogen bonds. Additionally, the later studies reveals interactions with the
rhamnose moiety3,4, which are the basis of substrate specificity of EarP, but were
not observed here.
The binding of EF-P likely follows the binding of dTDP-rhamnose as saturation
of EarP with dTDP-rhamnose was shown to increase affinity for EF-P4. Here EF-
P was shown to interact with EarP almost exclusively via the rhamnosylated N-
terminalKOW-likedomain. Thedomainon its own is sufficient for rhamnosylation
in vitro2. In agreement with this, the structure of the EarP-EF-P complex shows the
only the N-terminal KOW-like domain contacting EarP3,4. The interaction spans
a very large surface covering the N-terminal domain of EF-P which binds to the
entrance of the inter-domain cleft of EarP. In N. meningitidis EF-P binding induces
a domain rotation in EarP, but this is not observed in P. aeruginosa EarP3,4.
The putative catalytic residues were here proposed to be D13, D17 and/or
E273. The later studies indeed confirm the importance of these residues. D17 and
D13 directly interact with the Nη of R323,4. D17 is then seen in position suitable
for deprotonation of the R32 and was therefore proposed to be the base catalyst.
The exact role of D13 and E273 is unclear, but the active site residues undergo
extensive conformational changes during the reaction, so D13 and E273 may be
auxiliary residues facilitating those re-arrangements. Interestingly, in the dTDP-
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rhamnose complex D13 forms a hydrogen bond with the side-chain of Y2914.
Here Y291 was shown to be essential for rhamnosylation both in vivo and in vitro.
These residues together undergo a conformational change which would lead to
a clash with the rhamnose moiety in the dTDP-rhamnose complex4. Moreover,
the rhamnose moiety in the dTDP-rhamnose complex assumes an inactive state
with the sugar ring in a conformation incompatible with the SN2 reaction3. So
the conformation changes of residues such as D13, E273 and Y291 was proposed
to facilitate conformation change of the sugar ring priming the rhamnose for the
nucleophilic attack3,4.
Furthermore, R271 was here shown to be indispensable for EarP activity in vivo
and in vitro. Curiously, GT-B glycosyltransferases often utilize a positively charged
residues during the reaction as well53. The positively charged residues would
neutralize the emerging negative charge of the diphosphate during the transfer
reaction. R271 is in both the P. putida EarP structure presented here and in the P.
aeruginosa EarP4 structure binding the phosphate of dTDP. This together suggests
R271 as a promising candidate for the active site residue facilitating the leaving
group departure during the reaction.
In summary, the reaction mechanism of EF-P rhamnosylation emerges as fol-
lows. First, the ground state EarP binds dTDP-rhamnose. dTDP-rhamnose sta-
bilizes the active site loops and in turn facilitates EF-P binding. EF-P binding
induces further conformational changes in the active site loops. D17 then depro-
tonates R32, and further residues such as D13, E273 and Y291 force the rhamnose
to assume the active conformation. The R32 Nη then performs the nucleophilic
attack of the rhamnose further aided by R271, which facilitates the leaving group
departure by neutralizing the negative charge of the leaving diphosphate group
of the dTDP moiety. Rhamnosylation of R32 then results in steric tensions which
lead to the release of rhamnosylated EF-P. dTDP bound EarP is then recycled by
the release of the dTDP via unknown mechanisms back to the ground state.
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1.5 Materials and Methods
Major part of the experiments described in this chapter were carried our in the
laboratory of Prof Dr. Kirsten Jung under the supervision of Dr. Jürgen Lassak
and are published2,55,60. Therefore, not all experiments are described here and for
the details of these experiments please see the published literature.
1.5.1 Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy was used to study the struc-
ture and dynamics of EF-P, the rhamnosylation of EF-P, the structure of EarP and
the interactions of EF-P and EarP. The details of the experiments are already de-
scribed2,55,60, so the following only briefly summarizes the experiments discussed
in details in this study.
First, 13C and 15N labelled EF-P was assigned both in its unmodified and rham-
nosylated formusing the standard triple resonance assignment experiments52. The
spectra recorded for the assignment were 15N HSQC, HNCA, CBCACONH, and
HNCACB (the three later recorded using a constant time during 13C evolution).
Then, a set of experimentswas recorded in order to determine the configuration
of the anomeric carbon of the rhamnose attached to EF-P. A 13C-edited NOESY-
HSQC with simultaneous 13C and 15N evolution during t2 was recorded to assign
the resonances of the attached rhamnose. The 1JCH scalar coupling between the
anomeric carbon and directly bound proton (H1’-C1’) was then measured by
recording three gradient-enhanced 13C-HSQC experiments61 . The experiments
were measured with the 1H decoupling switched off during different parts of
the pulse sequence - once during acquisition to resolve the coupling in the 1H
direct dimension with 4096 points (160 ms acquisition time) and twice during 13C
evolution to resolve the coupling in the 13C dimension with 3584 points (63.6 ms)
or with 600 points (10.7 ms) to avoid resolving 13C-13C coupling. The resolved
peaks were fitted using the nlinLS built-in function of NMRPipe62 to determine
the scalar coupling.
Due to the large size of EarP (43 kDa) the resonance frequencies were assigned
using a 2H, 13C an 15N labelled sample. This allowed to acquire the spectra for the
triple resonance backbone assignment in TROSY mode63,64. The spectra recorded
for EarP assignment were 15N HSQC, HNCA, HNCACB, and CBCACONH all
recorded in TROSY mode.
The interactions of EF-P and EarP were studied by NMR titrations. A 15N
labelled protein was always titrated by an unlabelled interaction partner and the
progress of the titration was monitored by recording a 15N HSQC spectrum after
each addition. Unmodified EF-P was titrated by EarP to 1:2 EF-P to EarP molar
ratio with subsequent steps at 1:0, 1:0.5, 1:1, 1:1.5 and 1:2 ratios. Rhamnosylated
EF-P was titrated directly to 1:2 EF-P:EarP ratio. WT EarP was titrated by dTDP-
rhamnose to 1:5 EarP:dTDP-rhamnose molar ratios with steps at 1:0, 1:0.2, 1:1 and
1:3 ratios. The D13A and D17A EarP variants were titrated to 1:10 EarP:dTDP
rhamnose ratio without intermediate steps. The NMR titrations were analyzed by
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calculating the Chemical Shift Perturbations (CSP) as:
CSPNH =
√
(δHf − δHi)2 + ((δNf − δNi)/6.5)2 (1.1)
where δHi/Ni and δHf/Nf are initial and final proton/nitrogen chemical shifts, respec-
tively and 6.5 is a scaling factor accounting for nitrogen shifts spanning broader
range than proton shifts65.
The NMR experiments were measured on Bruker Avance III spectrometers
with a magnetic field strength corresponding to a proton Larmor frequency of 600
MHz (equipped with a Bruker TXI cryogenic probe head), 700 MHz (equipped
with a Bruker room temperature probe head), or 800MHz (equippedwith a Bruker
TXI cryogenic probe head). All measurements were done at 25◦C . The spectra
were all processed in NMRPipe62 using a gaussian window function and zero
filling and the analysis and assignment was done in CARA (http://cara.nmr.ch)
and CcpNmr Analysis66.
The backbone resonance assignments of EarP and EF-P have been deposited
to the Biological Magnetic Resonance Bank (BMRB) under the accession numbers
27091 and 27090, respectively.
1.5.2 X-ray crystallography
X-ray crystallography was used to obtain insights into the molecular structure and
the chemistry of EarP. The crystallization trials were set up with N-terminally
tagged His6-EarP at 8 mg/ml in 50 mM Tris, 100 mM NaCl, 1 mM DTT, pH 7.6
bufferwith 10mMTDP-Rhamnose. The trials were set up in the EMBLHeidelberg
Crystallization Facility using the Mosquito crystallization robot (TTP LabTech) in
MRC crystallization plates (2 wells, round bottom). The screens used the vapour
diffusion crystallization method in the hanging drop set up with a drop mixed of
100 nl of the protein samples and 100 nl of the mother liqour. The crystallization
was tested at 20◦C and 4◦C. The set of the commercial screens tested is listed
in Table 1.1. Eventually, the crystallization conditions were found in the JCSG+
screen (Molecular Dimensions) at 4◦C. The initial crystals did not diffract well, so
the condition was further refined in a custom design 24-well plate screen to 0.2 M
ammonium acetate, 0.1 M bis-Tris, 27% (w/v) PEG 3350, pH 6.0. The details of
the optimization screens are in the Supplementary Table 1, Supplementary Table 2
and Supplementary Table 3.
Several complete datasets were then collected at ID23-2 and ID29 at the Eu-
ropean Synchrotron Radiation Facility, Grenoble, France. First, a native dataset
extending to 2.3 Å was collected at ID23-1, but no suitable model was found to
phase the data by molecular replacement (MR). Therefore a seleno-methionine
(SeMet) derivative of EarP was crystallized and a full dataset extending to 3Åwas
collected at selenium absorption edge (λ = 0.97 Å) at beamline ID29. The space
group for both crystals was determined to be I4. The anomalous signal in the
SeMet dataset was used to phase the data using single-wavelength anomalous dis-
persion (SAD). The SAD phasing was done by Crank2 automatic pipeline67. The
structure factor amplitudes were estimated by Afro (N. S. Pannu, unpublished),
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Table 1.1 The crystallization screens tested for EarP.
Concentrations tested [mg/ml]
Screen Supplier 4◦C 20◦C
Classics Qiagen 8 8
JCSG+ Molecular Dimensions 8 8
PACT Molecular Dimensions 8 8
PEGS Qiagen 8 8
Wizard I+II Rigaku 8 8
The crystallization screen was done with 8 mg/ml EarP in 50 mM Tris, 100 mM NaCl, 1 mM DTT,
10 mM TDP-Rhamnose, pH 7.6 buffer.
the substructure detection was done by Crunch 268 and the density modification
was done in Solomon69. First, the structure was built using the anomalous dataset
by Phenix Autobuild70 and manual building in Coot71. The model was then used
for MR of the native high resolution dataset. The published structure was final-
ized by additional cycles of manual building in Coot and refining in Refmac72 and
is now available with structure factors in the Protein Data Bank under the PDB
accession code 5NV8.
Chapter 2
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2.1 Introduction
2.1.1 Translation regulation in Drosophila development
Development is a prominent example of biological processes governed by the reg-
ulation of gene expression73. This is probably the best documented on Drosophila
development74. During oogenesis the nurse cells load the developing oocyte with
maternally transcribed mRNAs of the maternal effect genes. The mRNAs are pro-
duced early but only to be used later during embryogenesis to help the embryo in
the synthetically taxing early development.
The maternal effect genes carry the origins of the dorsal-ventral (D-V) and
anterior-posterior (A-P) polarity. To define the anterior-posterior axis in the em-
bryo the maternal effect genes will produce protein gradients across the embryo.
These protein gradients will then regulate the expression of gap, pair rule and
segment polarity genes, which cause the segmentation of the embryo. This illus-
trates the instrumental need for temporal and spatial regulation of translation in
development. However, it does not explain the molecular mechanism behind the
temporal and spatial regulation of translation.
2.1.2 The mechanism of the anterior-posterior axis formation
Themolecular origins of the A-P polarization can be traced back to maternal activ-
ity during oogenesis. However, the A-P axis becomes morphologically apparent
only in late embryogenesis. The A-P axis formation starts with the secretion of
mRNAs of maternal effect genes into the oocytes by nurse cells. The maternal
effect genes induce polarization of the embryo75,76. bicoid is transcribed by the
nurse cells and supplied to the oocyte. The bicoid mRNA is then tethered to mi-
crotubules at the anterior pole of the oocyte77–80. The localization of bicoidmRNA
is necessary for anterior development81–83. The nurse cells also transcribe and
transport another maternal effect gene to the oocyte - nanos. The nanos mRNA
– 23 –
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is then concentrated to the posterior pole84, where it needs to be localized for
posterior development85,86. Two other maternal effect genes hunchback and caudal
are transcribed by the nurse cells and secreted to the oocyte, but their mRNAs
are distributed uniformly throughout the oocyte87,88. The mature oocyte then has
anterior localized bicoid mRNA, posterior localized nanos mRNA and uniformly
distributed hunchback and caudalmRNA. These RNAs remain dormant until fertil-
ization.
The oocyte is then fertilized, which triggers synthetic processes. During early
embryogenesis the nuclei devide rapidly without cytokinesis forming a syncytial
blastoderm. During this phase the maternally supplied mRNAs are translated.
The translation of bicoidmRNAcreates anA-PBicoid protein gradient79,89, whereas
the translation of nanosmRNA results in P-A Nanos protein gradient84. However,
the gradients are formed by different mechanisms - the Nanos gradient is formed
by translation regulation and localization90–92, whereas the Bicoid gradient forms
due to RNA localization79. Bicoid then suppresses the translation of maternal
caudalmRNA at the anterior93,94 andNanos suppresses the translation of maternal
hunchback mRNA at the posterior95–97. The embryo then starts to form cell mem-
branes and the syncytial blastoderm develops into cellular blastoderm. When
zygotic gene expression starts, Bicoid enhances the zygotic expression of hunch-
back87,98,99. As a result, a P-A gradient of Caudal protein100,101 and an A-P gradient
of Hunchback protein forms98. The resulting protein gradients then control a
group of zygotic genes named gap genes, which divide the embryo into distinct
units. The expression of gap genes together with pair rule and segment polar-
ity genes leads eventually to the segmentation of Drosophila embryo102. During
these processes the embryo begins gastrulation and the A-P axis for the first time
manifests morphologically.
In summary, it is first necessary to control spatially and temporally the transla-
tion of maternal effect genes (e. g. bicoid, nanos, caudal and hunchback) in order to
transform the maternal molecular polarization of the oocyte into a morphological
zygotic A-P axis in the embryo. However, surprisingly little is known about the
molecular mechanisms of the spatial and temporal translation regulation of these
RNAs5,92 despite the fact that the resulting protein gradients have been discovered
20-30 years ago. To fully understand the A-P axis formation in Drosophila it is
therefore necessary to elucidate molecular details of the translational regulation
of these genes.
Generally, spatial and temporal translation regulation of the maternal effect
genes is mediated by cis-acting elements within the regulated mRNA96,103, which
are targeted by trans-acting RNA binding proteins (RBPs)90,92,104–106. This leads
to either localization, translation suppression, translation enhancement or even
a combination of those mechanisms might be necessary92. For translation sup-
pression the emerging overarching mechanism seems to be a combination of cap-
dependent translation inhibition and deadenylation. The cap-dependent transla-
tion inhibition is typically driven by protein-protein interaction of the trans-acting
RBPs that directly or indirectly recruit cap-binding proteins such as eIF4E or a
4EHP107–109. This brings together the 5’ and 3’ end of the RNA in a non-productive
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Figure 2.1 The origin of the Hunchback gradient. Mature oocyte harbours several maternally
transcribedmRNAwhich, among others, include hunchback, bicoid and nanosmRNA. The hunchback
mRNA is distributed uniformly throughout the oocyte and late the embryo, but the bicoidmRNA
localizes to the anterior and the nanosmRNA localizes to the posterior. The bicoid and nanosmRNAs
are after fertilization translated intro steep gradients of Bicoid emanting from anterior and Nanos
emanting from posterior. Nanos then suppresses translation of hunchback mRNA at posterior,
whereas Bicoid stimulates the translation at anterior. As a result the gradient of Hunchback
protein forms during embryogenesis.
closed loop conformation preventing the initiation of translation110,111. The trans-
acting RBPs are also often reported to recruit the CCR4 deadenylase112,113, which
removes the polyA tails of the mRNAs priming them for degradation. Specific
details of the mechanism of regulation are probably the most well-known for the
suppression of hunchbackmRNA translation.
2.1.3 The suppression of hunchbackmRNA translation
TheHunchback protein gradient controls the gap genes responsible for abdominal
segmentation114,115. Therefore, the translation of hunchback mRNA is repressed at
the posterior by Nanos gradient95–97. The responsible cis-acting elements were
found within the 3’ UTR of the hunchback mRNA in two regions of conserved
sequence which were termed Nanos Response Elements or NRE96. Within each
NRE there are two stretches of absolutely conserved sequences which were called
BoxA (upstream) and BoxB (downstream). Nanos contains a C-terminal Zinc
Finger domain (Nanos ZnF)116,117. Zinc Finger domains are known to bind nucleic
acids and indeed Nanos ZnF binds RNA with high affinity but low specificity.
Additionally, mutations in NREs that disrupt hunchback mRNA suppression have
in vitro no effect on Nanos ZnF binding. Instead other proteins bind the hunchback
mRNA118.
One such protein is Pumilio. Pumilio has a C-terimal Homology Domain
(Pum HD) which binds the hunchback mRNA specifically6,119–122. Pum HD is
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essential for abdominal segmentation123, because it recruitsNanos to the hunchback
mRNA and the recruitment is Pum HD-dependent105. The molecular details of
the recruitment are explained by the structure of a ternary complex consisting
of Pum HD, Nanos ZnF and the mRNA6. Pum HD binds its putative binding
site overlapping with BoxB, whereas Nanos ZnF is seen interacting with a few
bases upstream. However, the structure reveals an additional helix at the very C-
terminus of Nanos, which was not previously observed117. This additional helix
extends out of the ZnF to interact with the C-terminal repeats of Pum which are
necessary for the recruitment of Nanos105. The remarkable observation regarding
the ternary Pum HD-Nanos ZnF-RNA complex is that the interaction of Nanos
ZnF is not specific enough to target Nanos to hunchbackmRNA, while at the same
time a stable binary complex Nanos and Pum is not observed. However, all
three components form a stable ternary complex, in which not only a functionally
essential Nanos-Pum interface is observed, but also sequence requirements are
seen for the bases Nanos ZnF is interacts with.
The N-terminal portion of Nanos is divergent and thought to be largely un-
structured. However, it was shown to interact with the CCR4-NOT complex112,
which deadenylates the polyA tail of mRNAs priming them for degradation124.
Pum is able to repress the RNA independently125, but this ability is irrelevant for
hunchback mRNA repression since Pum is expressed symmetrically throughout
the embryo126.
A putative model of the suppression of hunchback mRNA translation emerges
taken all the information together. The hunchbackmRNA translation is suppressed
by the ternary complex of Nanos and Pum bound to the NRE in hunchbackmRNA
3’ UTR. Pum provides specificity to the complex by recognizing the RNA via its
HD domain, but carries no information about the position within the embryo.
Nanos, on the other hand, shows very little specificity for the RNA, but due to
its gradient expression it holds the spatial information. Each of the two proteins
can repress an mRNA independently, but they need to come together to create the
Hunchback gradient as the repression has to be spatially restricted. This model
of hunchbackmRNA translation suppression proposes translation suppression via
the deadenylation pathway by the concerted action of Nanos and Pum. However,
it is incomplete.
There is a third protein which participates in the suppression of hunchback
mRNA translation called Brain tumor (Brat)106. Brat has a C-terminal NHL do-
main via which it interacts with the 3’ UTR of the hunchback mRNA at a binding
site upstream of and partially overlapping with the BoxA of NRE7,127,128. Further-
more, Brat interactswith the eIF4E-mimicd4EHP to inhibit translation initiation108.
However, Brat is, similarly to Pum, uniformly distributed106. Thus, it is unlikely
that Brat alone creates the gradient of Hunchback. Nevertheless, it remains un-
clear how exactly the activity of Pumillio, Brat andNanos is related. Two scenarios
are in principle possible: either Brat associates with the Pum-Nanos-RNA ternary
complex or Brat forms its own repression complex.
The quaternary complex of Pum-Nanos-Brat and the RNA could benefit from
the increased specificity brought by Brat explaining the necessity of Brat for hunch-
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Figure 2.2 Cis-acting and trans-acting elements in suppression of hunchback mRNA transla-
tion. The cis-acting element in hunchback mRNA translation suppression are elements located in
the 3’ UTR of the RNA termed Nanos Reponse Element 1 and 2 (NRE1 and NRE2). The full
sequence of each NRE is shown the grey box. The underline indicates two conserved sequences
in each NRE termed BoxA and BoxB. The trans-acting elements include the NHL domain of Brain
tumor (in cyan), the HD domain of Pumilio (in purple) and ZnF domain of Nanos (in green).
Each domain has its binding site indicated by a line of corresponding colour above the NRE2
sequence.6,7,95–97,106,119–122,127,128
back mRNA suppression106. Initially, a number of observations were made, sug-
gesting that this could indeed be the case. Yeast four hybrid assays identified
several point mutants in Pum HD, Nanos ZnF and Brat NHL that would abrogate
formation of the quaternary complex106. However, those did not turn out in the
light of newly available structural data to be the evidence of the interaction of Brat
with the Pum-Nanos-RNA complex6,7. The mutations in Pum HD or Nanos ZnF
span the Pum-Nanos interface formed by the additional helix of Nanos, whereas
the mutation in Brat NHL were later found to be located in the RNA interaction
surface. Later, Pum was shown to enhance the affinity of Brat for RNA128. This
could be interpreted as indirect evidence of the quaternary complex, but the sig-
nificance of this enhancement remains unclear as the authors themselves observe
that Brat and Pum in reporter assays suppress translation independently128.
Instead Brat could also function to repress hunchback mRNA independently.
Brat is able to specifically bind hunchbackmRNA and it has the ability to suppress
translation independently128. Based on current findings it is impossible to suggest
a specific architecture of such a suppression complex, but Brat would likely need
to associate with another factor to create the Hunchback gradient, because Brat is
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distributed throughout the embryo uniformly106.
In summary, it is clear that the available data are not sufficient to explain the
molecular details of hunchback mRNA translation suppression. Further research
in two directions seems crucial. First, better understanding of the pathways Brat,
PumandNanos employ for translational suppression andhow these are connected
is needed. This is deliberately not discussed in here as it is out of the scope of this
work, however others have done interesting research in this direction129. Second,
further investigation into the events upstream of the repression is crucial. This is
signified on the informative power of the structural studies of the PumHD-Nanos
ZnF-RNA and Brat NHL-RNA complexes. The structural information obtained
explain previouslymisunderstood biological data. A similar biophysical approach
is nowneeded to test the existence of the quaternary (or other potential) complexes
with Brat and to reveal their architecture and assembly.
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2.2 Aims
In order to elucidate how Pum, Brat and Nanos participate in the suppression of
hunchback mRNA translation a biophysical study aiming to answer the following
questions was carried out:
• DoBratNHL and PumHD interact in vitrodirectly in the presence or absence
of RNA?
• Do Brat NHL and Nanos ZnF interact in vitro directly in the presence or
absence of RNA?
• Can Brat NHL, Pum HD and Nanos form a quaternary protein-RNA com-
plex?
• What is the architecture of such a quaternary protein-RNA complex and how
does it assemble?
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2.3 Results
2.3.1 The interplay of Brain Tumor and Pumilio
The Brat NHL domain and the Pum HD domain were both reported to bind
hunchback mRNA specifically6,7,119–122,127,128. However, the interactions were often
studied by electrophoretic mobility shift assays (EMSAs), which can be a limited
method to report on in solution interactions quantitatively130. In case of Pum
HD-RNA interactions this in combination with inconsistencies in experimental
methods (e. g. using natively purified Pum HD in some studies, but refolded
Pum HD in others or using Homo Sapiens Pum HD instead of Drosophila Pum
HD120,122) led to inaccuracies in describing the interaction. Therefore, several
isothermal titration calorimetry (ITC) experimentswere performed in order clarify
the understanding of the RNA interactions.
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Figure 2.3 Overview of hunchback RNAs used. (a) The NRE2 RNA. The secondary structure is
indicated based on previous studies7. (b) The RNA with Brain Tumor (Brat) consensus motif.
(c) The RNA with Pumilio (Pum) consensus motif. (d) The poly-U NRE2 RNA (pNRE2). This
RNA is derived from the NRE2 RNA by adding uracils to the 3’ end and replacing the nucleotides
connecting Brat and Pum binding sites by uracils to prevent secondary structure formation. Brat,
Pum and Nanos binding sites are indicated by cyan, purple and green bars, respectively.
The binding of RNA by PumHDwas measured first (Figure 2.4). The primary
site which Pum HD binds within the hunchbackmRNA is a 8-nucleotide sequence
generally termed either Pumilio Response Element (PRE) or Pum consensus (Fig-
ure 2.3). The Pum consensus overlaps partially with BoxB, which can be found in
both NRE1 and NRE2. The sequence of Pum consensus is UGUAYAUA, where Y
is U in NRE1 and C in NRE2. Pum HD binds to Pum consensus with a KD of 18
± 3 nM. The KD decreases even lower to 2.3 nM when the interaction is measured
in the context of the full NRE2 RNA. The NRE2 RNA contains the full sequence of
NRE2 including the Brat binding site and connecting nucleotides (Figure 2.3). In
the titration with this RNA the high affinity binding is followed by a second lower
affinity event with a KD of roughly 2 µM. To test whether the second binding is
to the Brat binding site and whether secondary structure of the RNA influences
Pum binding another titration was measured with an RNA termed poly-U NRE2
(pNRE2). The pNRE2 is a derivative of the NRE2 with additional uracils at the 3’
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end and with the nucleotides connecting Brat and Pum binding sites replaced by
uracils. Since the NRE2 was shown to form a secondary structure7, the pNRE2
was designed to prevent the RNA from forming any secondary structure. The
pNRE2 titration revealed that Pum HD binds the RNA with two binding events
as well. The higher affinity event resembles the interaction with Pum consensus
with a measured KD of 26.3 ± 6.5 nM, whereas the second event resembles the
lower affinity binding event in NRE2 with a measured KD of roughly 2 µM. This
result suggests that PumHD is able to bind any RNAwith its consensus with high
affinity regardless of its context or the RNA structure and that PumHD also binds
weakly the Brat binding site.
(a)
N 0.947 ± 0.0048
KD 18 ± 3 nM
∆H1 -29.25 ± 0.245 kcal/mol
(b)
N1 1.10 ± 0.0188
KD1 26.3 ± 6.5 nM
∆H1 -16.73 ± 0.197 kcal/mol
N2 1.880 ± 0.0348
KD2 1923 ± 150.9 nM
∆H2 -30.82 ± 0.680 kcal/mol
(c)
N1 0.906 ± 0.0078
KD1 2.3 ± 0.8 nM
∆H1 -15.80 ± 0.311 kcal/mol
N2 1.440 ± 0.0120
KD2 1970 ± 94.4 nM
∆H2 -18.30 ± 0.720 kcal/mol
Figure 2.4 Isothermal titration calorimentry of Pumilio HD domain (Pum HD). (a) The binding
of Pum HD to Pum consensus RNA of the sequence UGUACAUA. (b) The binding of Pum HD to
poly-U NRE2 RNA (pNRE2). The pNRE2 is derived from the NRE2 RNA by adding uracils to 3’
end and replacing the nucleotides connecting Brat and Pum biding sites by uracils. (c) The binding
of Pum HD to NRE2 RNA.
Next, the interaction of Brat NHL with RNA was investigated by ITC (Fig-
ure 2.5). Brat NHL binds the sequence consisting of UUGUUG present within
BoxA of each NRE termed Brat consensus. Isolated Brat consensus RNA interacts
with Brat NHL with a KD of approximately 1.4 µM. The affinity of Brat NHL for
the NRE2 RNA is higher with a KD of approximately 1.2 µM. The µM KD is not
comparable to the affinity of Pum HD. However, when Brat NHL was measured
with pNRE2 the affinity increased to 17.5 ± 3.1 nM. This could mean that Brat
NHL is sensitive to RNA secondary structure as it was proposed previously7. In-
terestingly, Brat NHL binds the NRE2 RNA in a single binding event with a 1:1
stoichiometric ratio, but the titration with pNRE2 shows two binding events with
an order of magnitude difference in KD (Figure 2.5b versus Figure 2.5c).
Despite the fact that Pum HD also weakly binds the Brat binding site, it is
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(a)
N 0.574 ± 0.0113
KD 1422 ± 192.6 nM
∆H1 -12.24 ± 0.321 kcal/mol
(b)
N1 0.515 ± 0.0118
KD1 17.5 ± 3.1 nM
∆H1 -14.26 ± 0.214 kcal/mol
N2 0.633 ± 0.0103
KD2 407 ± 83.9 nM
∆H2 -5.79 ± 0.379 kcal/mol
(c)
N 1.06 ± 0.0170
KD 1190 ± 198 nM
∆H -4.90 ± 0.142 kcal/mol
Figure 2.5 Isothermal titration calorimentry of Brain Tumor NHL domain (Brat NHL). (a) The
binding of Brat NHL to Brat consensus RNA of the sequece UUGUUG. (b) The binding of Brat
NHL to poly-UNRE2 RNA (pNRE2). The pNRE2 is derived from theNRE2 RNAby adding uracils
to 3’ end and replacing the nucleotides connecting Brat and Pum biding sites by uracils. (c) The
binding of Brat NHL to NRE2 RNA.
(a)
N 1.14 ± 0.0118
KD 165 ± 24.5 nM
∆H1 -30.94 ± 0.451 kcal/mol
(b)
N 1.87 ± 0.0323
KD 990 ± 131.3 nM
∆H -4.10 ± 0.105 kcal/mol
(c)
N 1.12 ± 0.0670
KD 2910 ± 1370 nM
∆H -5.83 ± 0.713 kcal/mol
Figure 2.6 Isothermal titration calorimetry of combined Brain Tumor (Brat) and Pumilio (Pum)
binding. (a) The binding of the PumHDdomain to the poly-UNRE2 RNA (pNRE2) pre-incubated
withBratNHL. (b)Thebindingof BratNHL topNRE2pre-incubatedwithPumHD. (c)Thebinding
of Brat NHL to NRE2 RNA pre-incubated with Pum HD.
unlikely that Pum HD binding would be inhibiting Brat NHL binding as the
second binding event of Pum has higher KD than the first binding event of Brat
NHL. In fact Pum HD was shown to mildly increase the affinity of Brat NHL
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for RNA in EMSA7. To test the cooperativity quantitatively another set of ITC
measurements was performed (Figure 2.6). In the first two experiments, Pum
HD was pre-incubated with pNRE2 RNA, while Brat NHL was titrated and vice
versa. In the third experiment the NRE2 RNA was pre-incubated with Pum HD
and Brat NHL was titrated. These experiments no longer show high and low
affinity binding events. Furthermore, in pre-incubation experiments both Brat
NHLandPumHDshowsignificantly increasedKD in comparison to the analogous
experiments with free RNA (e. g. Figure 2.5b versus Figure 2.6b or Figure 2.5c
versus Figure 2.6c). Since the mild cooperativity of Brat NHL and Pum HD
in RNA binding was previously observed in EMSA7 analogous pre-incubation
experiments were measured orthogonally in EMSA (Supplementary Figure 2).
These experiments did not show any clear evidence of cooperativity between Brat
NHL and Pum HD binding either. Furthermore, ITC measurements when Pum
HDwas directly titrated by Brat NHL did not reveal any binding (data not shown).
2.3.2 Reconstitution of the hunchback mRNA suppression com-
plex
The lack of cooperativity in RNAbinding by BratNHLandPumHDdoes not point
to a stable ternary complex of Brat NHL and Pum HD. Such ternary complex
of two proteins bound to the hunchback mRNA was however reported for Pum
HD and Nanos ZnF6. Whether the ternary complex recruits Brat NHL remains
unclear, as no direct observation of the quaternary complex of Brat NHL, PumHD
and Nanos ZnF bound to the hunchback mRNA (Hunchback complex) has been
reported yet. To test the existence of Hunchback complex purified Brat NHL, Pum
HD and Nanos ZnF were mixed together with a 23-nucleotide NRE2 RNA in an
attempt to reconstitute the complex in vitro. The mixture then underwent size-
exclusion chromatography (SEC) where a broad peak with a maximum at elution
volume corresponding to a molecular weight of 77 kDa was observed (Figure 2.7).
The expected molecular weight of the complex is approximately 88 kDa, so the
identity of the peak was further validated by SDS-PAGE. The gel clearly shows
bands corresponding to Pum HD (MW 38.4 kDa), Brat NHL (MW 31.9 kDa) and
Nanos ZnF (10.6 kDa). The NRE2 RNA has a molecular weight of only 7 kDa, but
the UV trace of the SEC run readily showed strong absorption at 260 nm. Further
validation came from a measurement of the UV absorption spectra of the SEC
peak which showed a prominent absorption maximum at 260 nm confirming the
presence of RNA.
Hunchback complex was rather stable at 4◦C, and a repeated SEC run after a
week showed a single peak at the same elution volume. Thus, crystallization trails
were done in 14 different commercially available crystallization screens (Table 2.2).
The trials spanned a concentration range from 1.5 to 10.0 mg/ml, tested every
contemporary crystallization chemistry (e. g. PEG precipitants, salts, pH, PEG
smears, precipitant mixtures or alternative polymer precipitants) and were done
at both 4◦C and 20◦C. Unfortunately, none of the tested conditions produced
crystals, so an alternative crystallization approach was tested using carrier-driven
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Figure 2.7 The Hunchback complex formation. Hunchback complex was reconstituted in vitro by
mixing purified Brain Tumor NHL domain, Pumilio HD domain and Nanos Zinc Finger domain
with the NRE2 RNA and then performing size-exclusion chromatography. (a) A chromatogram
of a size-exclusion chromatography run of the reconstituted Hunchback complex on a HiLoad
16/600 Superdex 200 pg column (GE Healthcare). (b) SDS-PAGE analysis of the main peak from
size-exclusion chromatrography fractions.
crystallization131. To this end, PumHDwas fused to MBP using a GSGSGS linker.
However, the MBP fusion impairs the formation of Hunchback complex (data not
shown).
2.3.3 The interplay of Brain Tumor and Nanos
The attempts to directly crystallize Hunchback complex failed and so alternative
strategies to investigate the complex were necessary. As the interaction of Pum
and Nanos was described6 and the ITC experiments do not show any coperativity
between Brat NHL and Pum HD (subsection 2.3.1), the next obvious binary re-
lationship to investigate was between Brat NHL and Nanos ZnF. Nanos ZnF was
previously cloned, purified and assigned, and due to its rather small size provides
awell resolved 15NHSQC spectrum132. Such a spectrum is particularly convenient
for NMR titrations as any changes in it should be very well visible. Brat NHL is
roughly three times the size of Nanos ZnF so a potential interaction with Nanos
ZnF should not only manifest in chemical shift perturbations but also in a severe
decrease of signal intensity resulting from a change of the tumbling rate of Nanos
ZnF upon interaction with Brat NHL.
The samples of natively purified Nanos have been shown to be heterogeneous
- running as two bands on SDS-PAGE105,133. One of the species is still recruited
and crystallized in the ternary complex with Pum HD and RNA, but this hetero-
geneity is nevertheless visible in NMR as doubling of certain peaks suggesting
two alternative conformations in solution132. However, upon the addition of zinc
the alternative conformation disappears and the prevailing major conformation
is likely the active species as it was shown to bind RNA132. To study the Brat-
Nanos interaction the purified 15N Nanos ZnF was supplemented with zinc and
gradually titrated by Brat NHL (Figure 2.8). The 15N HSQC spectrum used to
monitor titration confirms the homogeneity of Nanos at the beginning of the titra-
tion. Interestingly, the overlay of spectra from the titration reveals chemical shift
perturbations of Nanos ZnF upon Brat NHL addition indicating an interaction.
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Chemical shift pertrubation of Nanos ZnF titrated by Brat NHL
Figure 2.8 The NMR titration of Nanos ZnF by Brat NHL. (a) Overlay of the 15N NMR spectra
monitoring the Nanos ZnF-Brat NHL titration. 15N Nanos ZnF was titrated by unlabelled Brat
NHL to 1:2 Nanos:Brat ratio. (b) Zoom-in of the peaks that shift the most throughout the titration,
including peak assignment labels. (c) The chemical shift perturbation (CSP) plot derived from the
titration experiment. The plot shows themagnitude of changes of Nanos backbone amide chemical
shifts for each residue calculated according to Equation 1.1. The full line indicates the mean, the
dashed line indicates the mean plus standard deviation. Residues which show higher CSP than
the mean plus standard deviation are colored in white.
The chemical shift perturbations map to a continuous surface in the N-terminal
half of Nanos ZnF. However, the perturbations are not particularly large and the
peaks move in the fast exchange regime, which is typical for weaker interactions.
It would be valuable to describe the interaction more and in an orthogonal
assay, such as ITC. However, that requires homogenous Nanos sample. This can
be achieved by supplementing zinc in the buffer. However, BratNHL tolerates zinc
only for the short course of the NMR titration, while ITC requires to dialyse both
proteins in the same buffer to avoid buffer mismatch and an overnight dialysis to
buffer with zinc precipitated Brat NHL. Alternatively, refolding Nanos was tested
to obtain a homogeneous active sample of Nanos ZnF which would not require
explicit zinc in a buffer. Unfortunately, even a previously published refolding
protocol for Nanos ZnF116 only yielded partially folded Nanos (data not shown).
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2.3.4 Characterization of the hunchbackmRNAsuppression com-
plex
The quaternary Hunchback complex comprising Pum HD, Brat NHL, Nanos ZnF
and the NRE2 RNAwas further studied by small-angle x-ray and neutron scatter-
ing (SAXS and SANS). SAXS and SANS both provide low resolution information
about the shape of a particle and its size. However, neutron scattering depends
mainly on the composition of the nuclei and changes drastically for different iso-
topes of the same element such as hydrogen anddeuterium. This is often exploited
to study structures of biomacromolecules using contrast variation. In the solution
of a protein complex both the protein and the buffer scatter. Varying the content of
D2O in the buffer and using 2H-labelled proteins then provides a chance to design
sample conditions in which certain parts of the complex are rendered invisible.
The scattering measured by contrast variation then provides further insights into
the internal structure of the complex of interest.
For Hunchback complex several samples were measured (fully listed in Ta-
ble 2.3). SAXS was measured on a completely protonated sample at 0% D2O.
SANS was measured on the same sample at 0% and 66% D2O. Further SANS was
measured on samples of the complex with all possible combinations of two 2H-
labelled proteins in complex with 1H RNA and the remaining 1H protein. Each of
the complexes was generally measured in 0% D2O buffer, where all components
are visible, in approximately 42% D2O, where the 1H protein is invisible, and in
approximately 65% D2Owhere the RNA is invisible and 1H protein exhibits weak
negative contrast.
Thirteen curves in total were obtained and are fully shown in Supplementary
Figure 3. First, Guinier analysis was done in order to evaluate the quality of the
data (summary in Table 2.1, fits in Supplementary Figure 4). The majority of the
curves consistently agrees on the same basic parameter of Hunchback complex -
the radius of gyration (Rg). This Rg can be derived from eight of the thirteen curves.
The remaining five curves show distinctly lower Rg. These include all samples of
the complex with 2H Brat and 2HNanos (labelled 2B1P2N) plus the sample of the
complex with 2H Pum and 2HNanos (labelled 1B2P2N) at 68% D2O. The decrease
of Rg in these curves suggests that the integrity of the complex was compromised.
Indeed, when the curves of the four different complexes measured at 0% D2O are
compared, the 2B1P2N sample shows clearly different trend in comparison with
the other samples (Supplementary Figure 3c). In fact, the curve of the 2B1P2N
complex at 0% D2O does not fit any of the roughly 5000 models of Hunchback
complex generated (described later). However, it fits very well a mixture of the
PumHD-Nanos ZnF-RNA and Brat NHL-RNA complexes (Supplementary Figure
3d). The 1B2P2N complex at 0%D2Ofits themodels of Hunchback complex rather
well and does not fit the mixture (Supplementary Figure 3e). However, the curve
of this complex at 68% D2O consistently across the whole range of Hunchback
complex models shows higher intensities at low q values, which is a common sign
of aggregation (Supplementary Figure 3f). It is unlikely that these curves provide
data about Hunchback complex of high enough quality, so only the eight curves
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Table 2.1 The basic parameters derived from the small-angle scattering data.
Sample
Guinier analysis P(r)
predicted I0Rg [Å] I0 Rg [Å] I0 Dmax [Å]
SAXS 39.6 66.8 39.5 64.8 128
1B1P1N 0% D2O 38.9 0.150 42.7 0.089 125 0.239
1B1P1N 66% D2O 39.6 0.059 41.8 0.035 129 0.056
1B2P2N 0% D2O 38.2 1.17 36.9 0.928 129 0.938
1B2P2N 41% D2O 36.1 0.306 36.6 0.276 127.5 0.271
1B2P2N 68% D2O 33.5 0.098 n.d. n.d. n.d. 0.050
2B1P2N 0% D2O 23.6 0.221 n.d. n.d. n.d. 0.808
2B1P2N 44% D2O 24.2 0.072 n.d. n.d. n.d. 0.176
2B1P2N 59% D2O 18.8 0.045 n.d. n.d. n.d. 0.065
2B1P2N 82% D2O 25.6 0.044 n.d. n.d. n.d. 0.000
2B2P1N 0% D2O 40.2 1.44 39.6 1.33 128 1.406
2B2P1N 33% D2O 40.0 0.633 39.68 0.557 132 0.671
2B2P1N 62% D2O 39.8 0.259 41.81 0.208 128 0.245
Rg refers to radius of gyration, I0 to forward scattering, Dmax to maximum distance and P(r) to
distance distribution function. The parameters grouped under Guinier analysis were calculated
by Guinier approximation, whereas the parameters grouped under P(r) were calculated from the
distance distribution function. The predicted I0 was calculated using SASSIE-web (https://sassie-
web.chem.utk.edu/sassie2/).
showing consistent data were analyzed further.
SAS reveals the followingparameters ofHunchback complex. TheRg ofHunch-
back complex is around40Å. Thedistance distribution function shows amaximum
distance of approximately 125-130 Åwith a peak of distances at approximately 30
Å (Supplementary Figure 5). The distance distribution function generally shows
a very asymmetric peak gradually tailing of in high distances often with addi-
tional local maxima in the tail, which suggests rather an elongated particle than a
sphere134.
The SAS data were then used in conjunction with the available high resolution
X-ray structures of Brat NHL-RNA and Pum HD-Nanos ZnF-RNA complexes to
model Hunchback complex. The X-ray structures were placed on single NRE2
RNA. The modelling was then done by preserving those parts that contain infor-
mation from the X-ray structures and sampling the available conformational space.
In practice the connecting part of the RNA not bound by any of the proteins was
first randomized and then simulated annealing was performed. This generated
5055models of possible structures ofHunchback complex. Then, scattering curves
were back-calculated at corresponding conditions for each of the model. The back
calculated curves were then fitted against the experimental curves obtaining a dis-
tribution of fits for each experimentally measured curve (Figure 2.9). The quality
of the fit was quantified in terms of χ2. Models that are in the top 0.22 quantile
of the χ2 distribution of each curve were selected to find the overall best fitting
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model of Hunchback complex (the points in two shades of blue in Figure 2.9).
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Figure 2.9 The fits of Hunchback complex models to the small angle scattering (SAS) data.
A set of 5055 models of Hunchback complex was calculated using the X-ray structures of the
components and scattering curves of each model at corresponding condition were back-calculated
and fit against the SAS data. Each line shows a distribution of χ2 values from all models for one
experimentally measured curve. The coloured points show the models found in the ensembles of
overall best fitting models (models in the top 0.22 quantile for each curve). The purple-blue points
indicate models in the major ensemble of 14 models, the cyan points indicate the 3 models in the
minor ensemble. The box indicates 0.25 to 0.75 interquantile range, the line in the box indicates the
mean and the grey points indicate the outliers.
That yielded 17 models models that reveal two well defined conformations of
Hunchback complex (Figure 2.10a). The major conformation ensemble comprises
14models inwhich Brat NHL is located in the vicinity of the additional C-terminal
helix of Nanos ZnF. The precision of the major ensemble is 8.4 Å RMSD to the
mean model of the ensemble. The minor conformation ensemble comprises only
3 models in which Brat NHL localizes to the C-terminus of Pum HD on the
opposite side of Pum HD than Nanos ZnF. The precision of the minor ensemble
is 5.5 Å RMSD to mean model of the ensemble. The imprecision of either of the
ensembles simply reflects the limits of SAS. The difference between the models
within the ensembles comes from rotation of Brat NHL about its own axis. Brat
NHL is a six-bladed β-propeller that has a six-fold rotational symmetry about its
axis. As SAS provides rotationally averaged scattering, the information about the
absolute rotation of Brat NHL is lost.
The model closest to the mean coordinates in each ensemble was selected as a
representative and its fits to the experimental curves were examined to compare
the ensembles (Figure 2.10b and Figure 2.10c). However, no obvious distinction is
visible between themajor andminor ensemble suggesting that both conformations
of Hunchback complex are equally possible. To resolve the ambiguity cross-
linking/mass spectrometry (XL/MS) data were collected.
Three sets of XL/MS data were acquired (Supplementary Figure 7). Two sets
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Figure 2.10 The best models of Hunchback complex based on modelling and small angle scat-
tering (SAS) data. (a) The top 17 models of Hunchback complex based on their overall fit to
the SAS data. The criteria to select the models was a χ2 of their fit in top 0.22 quantile for each
experimental SAS curve. The models fall into two ensembles based on their conformation - the
major ensemble comprising 14 models here depicted with Brat NHL domain coloured in shades
of purple-blue and the minor ensemble comprising 3 models here depicted with the Brat NHL
domain coloured in shades of cyan. Themodels are always aligned on PumHD. (b) and (c) The fits
of the representative model of each ensemble to the experimental SAS curves. The representative
model was selected as the model closest to the mean structure of the ensemble. The parentheses
state the χ2 of each fit.
come from 1.5 mg/ml Hunchback complex cross-linked with 0.2 mM and 1 mM
DSS, respectively. The third was obtained from 0.95 mg/ml Hunchback complex
cross-linked by 0.5 mM DSS. The 0.2 mM DSS with 1.5 mg/ml complex yielded
7 unique inter-molecular cross-links. The 1 mM DSS with 1.5 mg/ml complex
yielded 74 unique inter-molecular cross-links, while the 0.5 mM DSS with 0.95
mg/ml complex yielded 20 unique inter-molecular cross-links. The 1.5 mg/ml
concentration of the complex is likely to be suboptimal for cross-linking. Both
datasets acquired at the concentration show significant proportion of cross-links
that are obviously not possible within a single monomeric Huchback complex.
This includes cross-links when a residue is reported cross-linked to itself (two
identical peptides cross-linked), cross-links of residues within a domain that are
too distant to be cross-linked in a single molecule or cross-links linking the same
site of Brat NHL to the opposing poles of Pum HD. These cross-links clearly do
not describe a single monomer of Hunchback complex. At 0.95 mg/ml complex
this phenomena is not obvious, so the 0.5 mM DSS dataset was analyzed in more
detail (Figure 2.11,subsection 2.5.8).
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Figure 2.11 The cross-links of Hunchback complex. (a) The cross-links detected by cross-linking
0.95 mg/ml Hunchback complex by 0.5 mM DSS. The coloured lines indicate inter-molecular
cross-links, while the grey lines indicate intra-molecular cross-links. Only cross-links with xQuest
score greater than 25 are shown. The white gaps in Nanos ZnF highlight the residues showing
significant chemical shift perturbations (CSPs) in Nanos ZnF-Brat NHL NMR titration shown in
Figure 2.8. (b) The structure of the Pum HD-Nanos ZnF-RNA complex with highlighted CSPs
from Nanos ZnF-Brat NHL NMR titration and the cross-linked residues. The CSP from Figure 2.8
are plotted here in green-white gradient with green representing the least and white representing
the most perturbed residues in the titration. The blue spheres represent the Pum HD and Nanos
ZnF residues which Brat NHL cross-links to.
The dataset shows Brat NHL to cross-link to both Nanos ZnF and Pum HD.
Interestingly, Brat NHL cross-links to the C-terminus of Pum HD, which is also
the site of Nanos ZnF binding. Brat NHL is further cross-linked to K49 of Nanos
ZnF, which is in vicinity of the Nanos residues showing the largest chemical shift
perturbations upon titrating Brat NHL (Figure 2.8). Nanos K49 aligns with the
residues of PumHD, which Brat NHL cross-links to in a single continuous surface
(Figure 2.11b). The cross-links of Brat NHL both to Nanos ZnF and Pum HD
emanate from the same residues of Brat NHL. Collectively, the XL/MS could
suggest that in Hunchback complex Brat NHL, Pum HD and Nanos ZnF form a
tripartite interaction surface located at the C-terminus of Pum HD.
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The 0.5 mM DSS dataset was then used to repeat the modelling described
above. Again, the X-ray structures of the individual components of the complex
were used in modelling combining RNA randomization and simulated annealing
to generate possible structures of Hunchback complex. However, the XL/MS data
were used as additional distance restraints resulting in 4572models of the complex.
Subsequently, theoretical scattering curves were back-calculated for each model at
each condition and fitted against the experimental curves (Figure 2.12). The set
of models was then reduced to 55 models which are in the top 0.3 quantile of χ2
distributions for each of the eight experimental SAS curves. From the 55 models
top 10%models were selected according to distance restraint energy giving rise to
a final ensemble of 6 models (Figure 2.13a).
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Figure 2.12 The fits of Hunchback complex models generated using the cross-linking/mass-
spectrometry (XL/MS) data against the small angle scattering (SAS) curves. A set of 4572models
of Hunchback complex was calculated using the X-ray structures of the components and XL/MS
data. Scattering curves of each model at corresponding condition were back-calculated and fit
against experimental data. Each line shows a distribution of χ2 values from all models for one
experimentallymeasured curve. The pink points show themodels found in the ensemble of overall
best models (the top 10%models with the lowest distance restraint energy of the models in the top
0.3 quantile for each curve). The box indicates 0.25 to 0.75 interquantile range, the line in the box
indicates the mean and the grey points indicate the outliers.
The ensemble modelled based on the XL/MS data shows Brat NHL localized
to the C-terminus of Pum HD (Figure 2.13a). Brat NHL is positioned similarly
to the previously described minor ensemble (Figure 2.13b). However, the NHL
domain is oriented differently, in comparison to theminor ensemble it is rotated by
roughly 70◦ about its diameter. The precision of the ensemble is 8.3ÅRMSD to the
mean coordinates of the ensemble. The imprecision arises again from uncertain
rotational position of Brat NHL, which was not resolved by the addition of the
XL/MS data to modelling. The cross-links were then inspected in detail on the
structure with the lowest distance restraint energy to see the information they
bring to the modelling (Figure 2.14).
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Figure 2.13 The best models of Hunchback complex modelled using the cross-linking/mass-
spectrometry and small angle scattering (SAS) data. (a) The top 6 models of Hunchback complex
based on their distance restraint energy and overall fit to the SAS data. The ensemble was obtained
by finding the models with fits in the top 0.3 quantile for each experimental curve and selecting
the models with top 10% distance restraint energy. The models are always aligned on PumHD. (b)
The alignment of representative models of ensembles from modelling based only on SAS and on
XL/MS and SAS. The representative models are the models from the ensemble closest to the mean
structure (modelling based only on SAS) or the model with the lowest distance restraint energy
(modelling based on XL/MS and SAS). The colour code is the same as in Figure 2.10. (c) and (d)
The fits of the representative model frommodelling based on XL/MS and SAS to the experimental
scattering curves. The parentheses state the χ2 of each fit.
In total 12 crosslinks between Brat NHL and PumHDorNanos ZnFwere used.
However, only 5 of these are satisfied in the representative model of the ensemble
(Figure 2.14a). The crosslinks were also inspected in the context of the model with
the overall lowest distance restraint energy to ensure it is not the SAS fitting that
filters out conformations which satisfy the XL/MS data better. Interestingly, in
this model only 6 out of 12 cross-links between Brat NHL and Pum HD or Nanos
ZnF are satisfied (Figure 2.14b). A visual inspection of cross-links reveals that the
majority of the cross-links form in the lower half of BratNHL. The upper half of the
NHL shows only two cross-links to Nanos ZnF from the very N-terminus of Brat
NHL, which is likely to be flexible. The modelling yields a structure that does not
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satisfy the cross-links well for two reasons. First, the space Brat NHL can occupy
is limited by the RNA - it is sterically not possible for Brat NHL to rotate so that
the RNA interaction surface would be completely facing away from the complex,
because the NHL domain is approximatelly 30 Å high and the RNA is simply
not long enough to span this distance even in its most extended conformation.
Secondly, manual manipulation of Brat NHL indicates that cross-links to Pum
HD and Nanos ZnF cannot be fully satisfied simultaneously (Figure 2.14c). This
suggests that the Brat NHL-PumHD interface and Brat NHL-Nanos ZnF interface
are two separate interfaces and explains why simply adding the XL/MS data does
not yield an accurate model of Hunchback complex.
(a) (b)
(c)
Figure 2.14 The cross-links demonstrated onHunchback complexmodels. (a) The representative
model of the ensemble of Hunchback complex models modelled using the cross-linking/mass-
spectrometry and small angle scattering data with visualized cross-links. (b) The overall lowest
distance restraint energymodel from the aforementionedmodellingwith visualized cross-links. (c)
Amanually built model with duplicated Brat NHL illustrating the chance of the Brat NHL-Nanos
ZnF and Brat NHL-Pum HD cross-links to be satisfied better separately. Satisfied cross-links are
coloured green in each panel, unsatisfied cross-links are coloured blue in each panel.
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2.4 Discussion
The first informative conclusions can be drawn from the ITC experiments. Pre-
viously, it was shown that Pum is capable of binding hunchback mRNA at both
PumHD and Brat binding site with comparable affinity122. This naturally raises a
question about the interplay of Pum and Brat RNA binding. The results of the ITC
experiments indeed show that Pum HD is able to bind Pum binding site and the
Brat binding site, but the KD differs in three orders of magnitude (Figure 2.4). This
contrasts with the previously published similar affinity of Pum HD for both sites.
However, this discrepancy could arise from the different experimental set up. In
the published fluorescence anistropy assays the individual affinities for each site
were measured in independent experiments with two different RNAs that each
contained one of the two bindings sites. The ITC experiments reported here mea-
sure the two binding events on the same RNA simultaneously thus providing a
more realistic observation that Pum HD has a clear preference for its binding site.
The binding of PumHD to the Brat binding site is not strong enough to impair
Brat binding to the RNA (Figure 2.6c). On the contrary, Brat NHL was shown to
bind RNA mildy cooperatively with Pum HD7. The mechanism was proposed
to be unfolding of RNA structure as a result of Pum HD binding which would
increase the accessibility of the RNA for Brat NHL. However, the results here do
not indicate any cooperativity. In fact binding of Pum HD slightly increases the
KD of Brat NHL (Figure 2.6). When structured NRE2 RNA and unstructured
pNRE2 RNA are compared in terms of Brat NHL binding, Brat shows higher
affinity to the pNRE2, but this RNA contains a poly-U stretch and Brat NHL was
shown to interact with U-rich sequences7. Indeed, the ITC experiments show two
binding events when Brat NHL is titrated to pNRE2 and a previous study also
clearly showed that the affinity of Brat for RNA increases with the increase of Brat
binding sites128. This suggests that the increase of affinity observed for Brat NHL
with the pNRE2 originates rather in the introduction of another binding site.
To conclude, Brat NHL and Pum HD bind both specifically their respective
consensus binding sites. Pum HD is a stronger RNA binder. However, these two
interactions are in the context of a single NRE2 fairly independent as they are not
observed to significantly reinforce or impair each other. In addition, ITC assays
did not show any direct interaction of Brat NHL with Pum HD.
The interplay of Pum HD and Nanos ZnF has been recently elucidated in
the structure of Pum HD-Nanos ZnF-RNA complex6. The Brat NHL-Nanos ZnF
interaction remained unclear. The NMR titrations presented here reveal signs of
interaction of Nanos ZnF and Brat NHL in the absence of RNA. The interaction
seems rather weak. However, this study provides direct evidence of the existence
of the quaternary Hunchback complex of PumHD, Nanos ZnF, Brat NHL and the
NRE2 RNA and within that complex Brat NHL cross-links to Nanos ZnF.
The complete atomic structure of Hunchback complex remains elusive as none
of the extensive crystallization trials tested here found a crystallization conditions
yielding diffracting crystals. However, this study reveals some initial characteris-
tics of the complex and paves the way to describing the structure of the complex
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by integrative approaches.
The small angle scattering and cross-linking/mass-spectrometry data pre-
sented here indicate that Hunchback complex is rather extended than compact
and reveal that Brat NHL is localized in the vicinity of the N-terminus of Pum
HD, where Brat NHL interacts with the N-terminal portion of Nanos ZnF and
the Pum HDN-terminus likely in two independent interactions (Figure 2.11b and
Figure 2.14c).
The attempts to model a more detailed architecture of Hunchback complex
in here did not provide a unique solution. Nevertheless, the modelling provides
valuable suggestions about the possible identity of the complex. The modelling
approach presented here implicitly assumes that Brat NHL, Pum and Nanos ZnF
form a monomeric quaternary complex with the Hunchback mRNA and aims
to find a single conformation this complex adapts. The modelling fails when
either of the three assumptions are false - either the proteins interact differently in
the context of the quaternary complex in comparison to the X-ray structures, the
complex adapts multiple conformations or the complex is not monomeric.
There is no evidence suggesting that the interactions would change upon com-
plex formation. The interactions sites within the RNA are well resolved and the
experiments in here suggest that at least Brat NHL and Pum HD do not interfere
in RNA binding. Hence, drastic changes of the interaction in Hunchback complex
formation would be very surprising. However, no experimental data explicitly
describing the interaction of the individual domains with the RNA within the
Hunchback complex were obtained.
Multiple conformations of the complex in solution would explain why the
cross-links cannot be fully satisfied by a single conformation during themodelling.
This can be easily tested using the SAS data. In SAS, amixture of components gives
rise to a signal which is an average of the scattering of the individual components.
If the SAS data describe amixture ofmultiple conformations of the complex, fitting
a mixture of back-calculated scattering curves of multiple models should results
in a better fit. However, if the fit of the mixture is only as good as the best fitting
conformation, the data are most likely not describing a mixture of components.
Such a preliminary test was performed by fitting the SAXS curve with a mixture
of representative models of the major and minor ensembles obtained from the
modelling without XL/MS data. Interestingly, the mixture fits the data better
than the individual models (Supplementary Figure 8). However the quality of the
fits increases only minimally suggesting that even this mixture does not describe
the solution accurately. Therefore, a more sophisticated search for a mixture to fit
is required to test this hypothesis properly.
The third explanation why the modelling approach does not seem to converge
to a clear solution is that the assumption that Hunchback complex is monomeric is
false. Themodelling approach presented here does notmodel anything else than a
single monomer of the complex, so if the data describe any other than monomeric
state, the modelling will not provide a satisfying solution. In such a scenario the
cross-links describing the interaction within a monomer and between multiple
monomers would be then interpreted as describing interactions only within a
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monomer,whichwould result in a largeproportion of cross-links unsatisfied at any
modelled conformation and a fundamentally unrealistic model. It is worth noting
that XL/MS experiments on Hunchback complex at 1.5 mg/ml show a significant
proportion of cross-links that are physically impossible within a single monomer
of the complex. In fact, SAS and XL/MS are both quite sensitive towards minor
populations under certain conditions, so it is conceivable that the complex would
have a veryweak tendency to dimerize. The scattering intensity in SAS scales with
the square of the volumeof the particle, so one globular particle in amillionwith an
order ofmagnitude higher radius contributes to the signal equally as the remaining
599,999 smaller particles. This illustrates how even aminor population of particles
of larger volume can affect the scattering curve significantly. Furthermore, the SAS
data show adisagreement between the Rg and I0 determined fromGuinier analysis
and distance distribution function (Table 2.1), which often is a sign of forming
particles of higher molecular weight134. XL/MS essentially capture an immediate
snapshot of the solution state, so any equilibria between multiple states would be
visible. In summary, possibly even such a weak dimerization tendency could be
observable by SAS andXL/MSdata, thatwould still allow the complex to run as an
apparent monomer during size-exclusion chromatography. To test the possibility
that Hunchback complex is in such an equilibrium, it is necessary to interpret the
data accordingly. To model the hypothetical oligomer and compare how well a
mixture of a monomer and the oligomer fits the experimental data. The existence
of such an oligomer would then need to be confirmed by orthogonal experiments.
Then, its relevance for function would be the question of primary importance.
However, the 3’ UTR of HunchbackmRNA contains two NREs, so it is conceivable
to imagine a monomer of Hunchback complex assembling on each single NRE
and such a monomer forming a higher order dimer structure. Moreover, Brat also
contains a Coiled-Coil domain and its recently solved structure reveals a dimer135.
Lastly, a more detailed understanding of the interplay between Brat NHL and
Nanos ZnF is essential to properly understand the architecture of Hunchback
complex. Therefore, follow-up experiments are absolutely crucial.
The conclusions drawn from this study may seem fairly limited. However,
Hunchback complex has been an elusive object of interest for approximately three
decades. This study paves an alternative way to elucidate Hunchback complex
architecture using integrative structural biology.
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2.5 Materials and Methods
2.5.1 Cloning, protein expression and purification
Pumilio Homology Domain
The Pumilio Homology Domain (Pum HD) was prepared as previously de-
scribed128,136,137. The pHUE Pum HD vector was kindly provided by Dr. Inga
Loedige. The vector carries a Pum HD construct encompassing Pum residues
1093 to 1426 fused by a short linker containing Usp2cc cleavage site to a His6-
Ubiquitin tag. The vector carries an Ampicillin resistance marker. To express
Pum HD the vector was transformed into E. coli BL-21(DE3) Rosetta cells. The
cells were grown until OD600 of 0.6-1.0 at 37◦C. The protein expression was in-
duced by the addition of IPTG to 1 mM final concentration and the protein was
expressed at 23◦C overnight.
The cells were harvested by centrifugation at 5000 rpm at 4◦C for 40 minutes.
Then, the cells were resuspended in 50 mM Tris, 1 M NaCl, 5% glycerol, 10 mM
Imidazol, pH 8.0 with 1 mg/ml lysozime, 1 µg/ml DNase I, 2 µg/ml RNase and
protease inhibitors tablets (1 per 50 ml, Roche cOmplete) and incubated for 20
minutes on ice. The cell lysis was completed by sonication. Then, the lysate
was spun at 18000 g at 4◦C for 60 minutes. The supernatant was loaded on a
HisTrap HP 5 ml column (GE Healthcare) and Pum HD was eluted using 10
- 100 mM Imidazole linear gradient followed by 250 mM Imidazole. Fractions
containing PumHDwere pooled and cleaved by Usp2cc during overnight dialysis
to 50 mM Tris, 150 mM NaCl, 1 mM DTT, pH 7.4. The Pum HD was separated
from theHis6-Ubiquitin andHis6-Usp2cc by reversing the previous Nickel affinity
chromatography. In the final step PumHDwas concentrated and further purified
by SEC on the HiLoad 16/600 Superdex 75 column (GE Healthcare) in the same
buffer.
Pumilio Homology Domain and Maltose-binding protein fusion
A set of Maltose-binding protein (MBP) fusion constructs of Pum HD was
designed for additional crystallization trials. The Pum HD costruct from pHUE
Pum HD vector was cloned in parallel into the pMALX vector system138 (kindly
provided by the author) and a modified pETM-41 vector. The pETM-41 plasmid
was modified by replacing the linker (including the cleavage site) with a GSGSGS
(modified by Kevin HaubrichM.Sc., the vector provided by EMBL Protein Expres-
sion and Purification Facility). The pMALX vectors carry an Ampicillin resistance,
whereas the pETM-41 carries a Kanamycin resistance. The pETM-41 PumHDwas
optimized for expression and purification as follows.
The vector was transformed in E. coli BL-21(DE3) Rosetta cells. The cells were
grown at 37◦C until OD600 of 0.6-1.0 and then induced by the addition of IPTG to
a final concentration of 1 mM followed by expression at 23◦C overnight.
The cells were then harvested as for Pum HD and resuspended in the same
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buffer, but without Imidazole. The same procedure as for Pum HD followed, but
Pum HD MBP was purified using a MBPTrap HP 5 ml column (GE Healthcare).
Pum HD MBP was eluted by a gradient of 0 to 10 mMMaltose in the lysis buffer.
The protein was then dialysed into 50 mM Tris, 150 mM NaCl, 1 mM DTT, pH
7.4. Lastly, Pum HD MBP was loaded to a HiTrap HP Heparin 5ml column (GE
Healthcare) and then eluted by 150 mM to 1.5 M NaCl gradient.
Brain Tumor NHL domain
The residues 756 to 1037 of Brain Tumor (Brat NHL) were cloned by Dr. Jaelle
Foot into the pHUE vector136,137 resulting in a construct similar to the Pum HD
construct with His6-Ubiquitin fusion. The expression and purification of Brat
NHL was carried out as for the Pum HD construct with the exception of the last
purification step. After overnight dialysis and cleavage Brat-NHL was loaded on
in series connected HisTrap HP 5 ml and HiTrap HP Heparin 5ml columns (both
GE Healthcare). First, Brat NHL was eluted by a 150 mM to 1.5 M NaCl gradient.
Then, the His6-Ubiquitin tag and His6-Usp2cc were eluted by 1M Imidazole.
Nanos Zinc Finger domain
The Nanos construct used in this study was cloned and its expression was
optimized by Sophie Winter, M.Sc.132. The construct comprises the residues 301-
392 of Nanos, which cover the Zinc Finger domain of Nanos (Nanos ZnF), in
pETM11 SUMO vector (EMBL Protein Expression and Purification Core Facility).
The vector contains Nanos ZnF fused by a linker with SenP2 cleavage site to
SUMO3 protein with His6 tag and carries a Kanamycin resistence marker.
To obtain Nanos ZnF the pETM11 SUMO vector was transformed into E. coli
BL-21(DE3) Rosetta cells. The cells were grown at 37◦C until OD600 of 0.6-1.0. The
expression was induced by the addition IPTG to 0.3 mM final concentration and
the protein was expressed at 16◦C overnight.
The cells were harvested by centrifugation at 5000 rpm at 4◦C for 40 minutes.
Then, the cells were resuspended in 50 mM Tris, 500 mM NaCl, 1 mM DTT, 10
mM Imidazole, pH 8.0 with 1 mg/ml lysozime, 1 µg/ml DNase I, 2 µg/ml RNase
and protease inhibitors tablets (1 per 50 ml, Roche cOmplete). After 20 minutes
incubation, the cell lysis was completed by sonication. Then, the lysate was spun
at 18000 g at 4◦C for 60 minutes. The supernatant was loaded on HisTrap HP 5 ml
column (GE Healthcare) and Nanos ZnF was purified using a 10 - 100 mM linear
Imidazole gradient followed by 250 mM Imidazole. Fractions containing Nanos
ZnF were pooled and cleaved by Sen2P during overnight dialysis to 50 mM Tris,
150 mM NaCl, 1 mM DTT, pH 7.4. Nanos ZnF was then loaded to HisTrap HP 5
ml and HiTrap HP Heparin 5ml columns (both GE Healthcare). First, Nanos ZnF
was eluted by a 150 mM to 1.5 M NaCl gradient. Then, the His6-SUMO3 tag and
the His6-SenP2 were eluted by 1M Imidazole.
On some occasions throughout this study the purified Nanos ZnF was further
refolded by the following procedure. First, Nanos ZnF was dialysed to 6M Urea,
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50 mM Tris, 150 mM NaCl, 20 mM DTT, 20 mM EDTA, pH 7.4. Then, Nanos ZnF
was dialysed twice to 50 mM Tris, 150 mM NaCl, 2 mM ZnSO4, pH 7.4.
Brain Tumor Coiled-Coil domain
To study the Brain Tumor Coiled-Coil domain (Brat CC) a construct was de-
signed spanning residues 375 to 530 of Brat. The Brat CC construct was cloned
in pETM11 SUMO vector with a linker containing SenP2 cleavage site and a His6-
SUMO3 tag carrying Kanamycin (EMBL Protein Expression and Purification Core
Facility). The expression and purification of Brat CC followed the same protocol
as Pum HD except that Brat CC was kept in 50 mM Tris, 1 M NaCl, 5% glycerol,
pH 8.0 buffer until the size-exclusion chromatography step.
Expression media and isotope labelling
The choices of media used for the expression of desired proteins followed the
same general rules. All unlabelled proteins were expressed in standard Lysogeny
broth (LB) medium. M9 minimal medium was used for isotope labeling with 13C-
glucose and/or 15N-NH4Cl as the sole carbon and nitrogen source, respectively. To
obtain deuterated proteins the M9 media was prepared in D2O and, if necessary,
2H-glucose was used as the sole carbon source for perdeuteration.
2.5.2 Hunchback complex formation
The quaternary protein-RNA complex which suppresses HunchbackmRNA trans-
lation was investigated in this study. It consisted of Pum HD, Brat NHL, Nanos
ZnF and the Nanos Response Element 2 of Hunchback mRNA (NRE2 RNA). The
sequence of NRE2 RNAwas 5’ UUGUUGUCGAAAAUUGUACAUAA 3’. Hunch-
back complex was reconstituted as follows. First, Pum HD, Nanos ZnF and NRE2
RNA were diluted to 10 µM and Brat NHL was diluted to 20 µM. Diluted Pum
HD was then added to NRE2 RNA, the mixture was shortly incubated on ice,
then Nanos ZnF was added, the mixture was again shortly incubated on ice and
eventually, Brat NHL was added. The same volume of all proteins was added, so
the complex was prepared by incubating the Pum HD, Nanos ZnF, NRE2 RNA
and Brat NHL in 1:1:1:2 molar ratio. The mixture was then concentrated by a
concentrator with a 3 kDA cutoff to around 1 ml. Then, SEC was used to purify
the complex using the HiLoad 16/600 Superdex 200 pg column (GE Healthcare).
The SEC run was analyzed by SDS PAGE.
2.5.3 Electrophoretic mobility shift assays
Electrophoretic mobility shift assays were used to asses cooperativity in RNA
binding by Brat NHL and PumHD. All RNA-binding reactions were performed in
50 mMTris-HCl, 150 mMNaCl, 1 mMDTT, 10 % [v/v] glycerol, pH 7.4 buffer. Re-
actions were equilibrated for 1 hour at 4◦C. Next, the samples were resolved on 6%
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native polyacrylamide gel in 0.5x TBE at 4◦C for 3-4 hours. Each reaction contained
a radiolabeled probe (1 nM NRE2 RNA) which was obtained by 5’ end labeling
with T4 Kinase (NEB) and ATP [γ-32P] (Hartmann Analytic). Gels containing ra-
dioactive RNAs were dried onto Whatman filter paper. The radioactive gels were
then exposed to a storage phosphor screen (GE) for 16 hours. EMSAswere imaged
with a Typhoon Trio imager (GE Healthcare) and subsequently quantified using
ImageQuant TL software.
2.5.4 Nuclear magnetic resonance spectroscopy
Nuclear magnetic resonance (NMR) spectroscopy in this study was mostly used
to investigate the interactions between the components of Hunchback complex.
The main interest was the potential interaction of Brat NHL with Nanos ZnF. For
that the resonance assignments of Nanos ZnF and Brat NHLwere previously done
by Sophie Winter, M.Sc.132 and Dr. Janosch Hennig (unpublished) and therefore
shall not be reported here. NMR titrations were performed to test the Nanos
ZnF-Brat NHL interaction. A 15N labelled Nanos ZnF (prepared as described in
subsection 2.5.1) was titrated by adding unlabelled Brat NHL to 1:0, 1:1 and 1:2
ZnF:Brat NHL ratio and each step of the titration was monitored by recording a
gradient-enhanced 1H, 15N-HSQC spectrum. The NMRmeasurements were done
on a Bruker Avance III spectrometer with a magnetic field strength corresponding
to an 800MHz proton Larmour frequency equippedwith a Bruker TXI cryo-probe
head. The measurements were done at 25◦C in 50 mM Tris, 150 mM NaCl, 1 mM
DTT, pH 7.4 buffer. The spectra were processed using NMRPipe62. To analyze the
NMR titrations chemical shift perturbations (CSP) were calculated according to
Equation 1.1.
2.5.5 X-ray Crystallography
Hunchback complex was prepared as described in subsection 2.5.2 to attempt
crystallization. All crystallization trials were set up with the complex in 50 mM
Tris, 150 mM NaCl, 1 mM DTT, pH 7.4 buffer. The complex was first concen-
trated in a 3 kDa cutoff concentrator to 10-15 mg/ml. The sample was then spun
down to remove potential precipitate in a table top centrifuge at max speed for 10
minutes. Then, the sample was diluted to desired concentrations and the crystal-
lization trials were set up in the EMBL Heidelberg Crystallization Facility using
the Mosquito crystallization robot (TTP LabTech) in MRC Crystallization plates
(2 wells, round bottom). An extensive set of commercial screens was tested at
various protein concentrations. The full list including the sample concentrations
used can be found in Table 2.2. The automated commercial screens used a vapour
diffusion crystallization method in the hanging drop set up with a drop made of
100 nl of the protein samples and 100 nl of the mother liquor. The crystallization
was tested at 20◦C and 4◦C.
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Table 2.2 The crystallization screens tested for Hunchback complex.
Concentrations tested [mg/ml]
Screen Supplier 4◦C 20◦C
Classics Qiagen 1.5, 3.0, 5.13, 10.0 1.5, 3.0, 5.13, 10.0
JCSG+ Molecular Dimensions 1.5, 3.0, 5.13, 10.0 1.5, 3.0, 5.13, 10.0
PACT Molecular Dimensions 1.5, 3.0, 5.13 1.5, 3.0, 5.13
PEGS Qiagen 1.5, 3.0, 5.13 1.5, 3.0, 5.13
Wizzard I+II Rigaku 1.5, 3.0, 5.13, 10.0 1.5, 3.0, 5.13, 10.0
Natrix Hampton Research 1.5, 3.0, 5.13, 10.0 1.5, 3.0, 5.13, 10.0
Nucliex Qiagen 1.5, 3.0, 5.13, 10.0 1.5, 3.0, 5.13, 10.0
MPD Qiagen 1.63, 2.13, 2.63, 3.13, 3.63, 4.13, 4.63, 5.13 -
AmSO4 Qiagen 1.5, 3.0, 5.0 3.0, 5.0
MIDAS Molecular Dimensions 1.5, 3.0, 5.0 1.5, 3.0, 5.0
Morpheus Molecular Dimensionns 1.5, 3.0, 5.0 1.5, 3.0, 5.0
PEGs II Qiagen 1.5, 3.0, 5.0 3.0, 5.0
SaltRX Hampton Research 1.5, 3.0, 5.0 3.0, 5.0
The BCS screen Molecular Dimensions 3.0 3.0
2.5.6 Small-angle scattering
Small-angle scattering (SAS) was used in this study to obtain low resolution infor-
mation about the shape and structure of Hunchback complex.
The overall shapes of the complex were investigated by small-angle X-ray
scattering (SAXS). The complex was prepared unlabelled as described in sub-
section 2.5.2. Prior to the measurements the samples were concentrated to 3.7
mg/ml. Hunchback complex was measured in 50 mM Tris, 150 mM NaCl, 1 mM
DTT, pH 7.4 buffer at 25◦C.
The SAXS measurements were done with the assistance of the beamline scien-
tists at theBM29beamline in theEuropeanSynchrotronRadition Source, Grenoble,
France. The samplesweremeasured in the constant flowmode to reduce radiation
damage, using a 2D Pilatus detector and X-rays of λ = 1.008 Å.
The complexes for SANS measurements were prepared as described in sub-
section 2.5.2. Multiple samples were prepared with various combinations of
perdeuterated subunits. A detailed list of the samples is in the Table 2.3.
The SANS measurements were done with the assistance of Dr. Frank Gabel
and Dr. Anne Martel at D22 instrument at the Institute Laue–Langevin, Grenoble,
France. In each measurement 200 µl of the sample were measured in Hellma R©
100QS quartz cuvettes. The following set of standards was always measured: the
empty beam, an empty quartz cell, a boron sample and a calibration curve of a
buffer with varying D2O content. The boron sample was measured for 5 minutes,
the empty cell for 10 minutes, the buffers for 20 minutes each and the samples of
Hunchback complexweremeasured for 60minutes each. Sample transmissionwas
measuredprior to eachmeasurement for 1minute. Thewavelenght of the neutrons
used was 6 Å. The measurements were done with a laterally shifted detector to
obtain the best q rangewhile reducing the time requirements for themeasurement.
This allowed to collect data faster for the whole q range that contained useful
information in a single measurement. Hunchback complex was measured at 4
meters detector and collimator distance. The transmission measurements of the
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buffers with different D2O content were used to calculate a calibration curve for
the determination of the actual exact D2O concentration in Hunchback complex
samples.
All experimental curves were buffer subtracted and potential initial points
showing signs of aggregation were removed in PRIMUS139. The data was further
analyzed by various other software of the ATSAS package140 and in ScaÅtter141.
Table 2.3 The list of samples for small-angle scattering measurements.
Sample Perdeuteration scheme Concentration [mg/ml] D2O concentration [%]Brat NHL Pum HD Nanos ZnF NRE2 RNA
SAXS 1H 1H 1H
1H
3.7 0
1B1P1N 0% D2O 1H 1H 1H 3.7 0
1B1P1N 66% D2O 1H 1H 1H 3.7 66
1B2P2N 0% D2O 1H 2H 2H 5.0 0
1B2P2N 41% D2O 1H 2H 2H 4.3 41
1B2P2N 68% D2O 1H 2H 2H 4 68
2B1P2N 0% D2O 2H 1H 2H 4 0
2B1P2N 44% D2O 2H 1H 2H 4 44
2B1P2N 59% D2O 2H 1H 2H 4 59
2B1P2N 82% D2O 2H 1H 2H 4 082
2B2P1N 0% D2O 2H 2H 1H 4 0
2B2P1N 33% D2O 2H 2H 1H 4 33
2B2P1N 62% D2O 2H 2H 1H 4 62
2.5.7 Isothermal titration calorimetry
Isothermal titration calorimetry measurements were done to determine the bind-
ing parameters and kinetics of the purified proteins interacting with RNAs. Sets
of experiments were measured for both the NRE2 RNA and the pNRE2 RNA (for
full sequences see subsection 2.5.2). The pNRE2 RNAmeasurements were done in
20 mM Tris, 150 mM NaCl, pH 7.4 and the NRE2 RNA measurements were done
in 50 mM Tris, 150 mM NaCl, 0.5 mM TCEP, pH 7.4 buffer.
Themeasurements involving theNRE2 RNAwere all done onMicroCal PEAQ-
ITC instrument (Malvern) at 20◦C. TheNRE2 RNAwas always first snap-cooled by
incubating it shakingat 65◦Cand thenquickly transferring it to ice for an incubation
of at least 20 minutes. The snap-cooling was done to ensure the RNA adapts
its thermodynamically most favoured confirmation. The pNRE2 measurements
were done on the iTC200 (MircoCal) at 20◦C. pNRE2 RNA is designed to have no
propensity to form secondary structure, so for the measurements including this
RNA the samples were just titrated directly. The samples were always degassed
prior to the titration. The proteins at high concentrations in the syringe were then
titrated to the diluted NRE2 RNA in the cell. The titrations were performed with
an initial injection of 0.4 µl followed by either 12, 15 or 20 injections of either 3,
2.5 or 2 µl, respectively. The number of injection was selected according to the
enthalpy change for the best compromise between the amount of signal and the
maximum number of points. The initial delay and the delay between injections
were set to 60 and 150 seconds, respectively. The samples were stirred at 750 rpm
and the instrument feedback was set to high. The reference power was set to 10
µcal/s.
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Table 2.4 The overview of the isothermal titration calorimetry measurements.
Experiment Cell Cell concentration [µM] Syringe Syringe concentration [µM] Injections Injection size [µl]
Figure 2.4a Pum consensus RNA 30 Pum HD 300 13 3 (0.4)
Figure 2.4b pNRE2 RNA 20 Pum HD 400 21 2 (0.4)
Figure 2.4c NRE2 RNA 20 Pum HD 400 16 2.5 (0.4)
Figure 2.5a Brat consensus RNA 30 Brat NHL 290 21 2 (0.4)
Figure 2.5b pNRE2 RNA 30 Brat NHL 390 20 2
Figure 2.5c NRE2 RNA 25 Brat NHL 375 13 3 (0.4)
Figure 2.6a pNRE2 RNA + Brat NHL 20 Pum HD 440 21 2 (0.4)
Figure 2.6b pNRE2 RNA + Pum HD 20 Brat NHL 430 21 2 (0.4)
Figure 2.6c NRE2 RNA + Pum HD 24 Brat NHL 375 13 3 (0.4)
Part of the measurements were performed by Dr. Vladimir Rybin and Dr.
Karthryn Perez, who also provided further support. The instrumentation was
provided by the EMBL Protein Expression and Purification Core Facility.
2.5.8 Cross-linking
Cross-linking and mass spectrometry (XL/MS) was used to obtain distance re-
strains for the modelling of Hunchback complex. All XL/MS experiments were
done with the complex reconstituted as described in subsection 2.5.2 and DSS as
the cross-linking reagent. The cross-linking reaction was done in 20 mM HEPES,
150 mM NaCl, 1 mM DTT, pH 7.4 buffer and followed a previously published
protocol142.
First, a 1.5 mg/ml Hunchback complex was cross-linked by four different
concentrations of DSS - 0.1 mM, 0.5 mM, 1 mM and 2.5 mM. The individual
proteins at same molar concentrations were cross-linked as controls by 1 mM
DSS. The cross-linked samples together with not cross-linked proteins were then
analyzed by SDS PAGE. The cross-linking was then repeated to collect the data
with an equimolar mixture of 1H-DSS and 2H-DSS at 0.2 mM, 0.5 mM and 1 mM
concentration. The 0.2 mM DSS reaction was done once at 1.5 mg/ml complex
concentration, the 0.5 mM DSS reaction was done in two replicates at 0.95 mg/ml
complex concentration and the 1 mM reaction was done in three replicates at 1.5
mg/ml complex concentration.
First, 50 mM DSS dissolved in DMF was added up to the desired cross-linking
reagent concentration of 1.5 mg/ml complex in 200 µl. The reaction mixture was
then incubated shaking at 37◦C for 30 minutes. 1 M NH4HCO3 was then added
to a final concentration of 50 mM to quench the reaction and the mixture was
incubated at 37◦C for 20 minutes. A few µl of the samples were analyzed by SDS
PAGE and the sample was kept at 4◦C overnight. The next day, 10 M Urea in
250 mM NH4HCO3 was added to 8 M final Urea concentration. Then, RapiGest
surfactant (Waters) dissolved in 10 mM NH4HCO3 was added to 1 mg/ml final
concentration. The mixture was then sonicated on ice by a single 60s pulse at 10%
power. 1 M DTT in H2O was then added to 10 mM final concentration and the
mixture was incubated shaking at 37◦C for 30 minutes. Then, 100 mM IAA in H2O
was added to 15 mM final concentration and the mixture was incubated shaking
at 37◦C for 30 minutes in the dark. Next, 0.1 µg/ml LysC (Wako) dissolved in 10
mM NH4HCO3 was added in 1:100 protease:protein ratio. The mixture was then
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incubated shaking at 37◦C for 3.5 hours. HPLC grade H2O was then added to
dilute the sample to 1.5 M Urea concentration. Then, 1 mg of Trypsin (Promega)
dissolved in supplied buffer was added in 1:50 protease:protein ratio and the
sample was incubated shaking 37◦C overnight. On the third day, TFA was added
to 1% v/v final concentration. The sample was then incubated shaking 37◦C for
30 minutes. At the end, the sample was spun in a table top centrifuge to remove
any potential precipitate for 20 minutes at max speed . Finally, the samples were
submitted to the EMBL Proteomics Core Facility for the MS analysis.
2.5.9 Modelling
Structural modelling was done to obtain insights into the architecture of the com-
plexes using the Crystallography & NMR System (CNS)143,144. The Pum HD-Brat
NHL-pNRE2 RNA complex wasmodelled based on the starting structures of Pum
HD in the complexwith the RNA (PDB ID 1M8W)145 and Brat NHL in the complex
with RNA (PDB ID 4ZLR)7. Hunchback complex was modelled using the same
Brat NHL-RNA complex structure and using the PumHD-Nanos ZnF-NRE2 RNA
complex structure(PDB ID 5KL1)6. The BratNHL-RNAcomplex structure actually
contains twoNHL domains bound to a single long RNA, so for the modelling only
the one bound to the reported Brat binding site on theHunchbackmRNAwas used.
The startingmodelswere built bymerging together the individual RNAcomplexes
and connecting and extending the RNAs from the structures by nucleotides ac-
cording to the RNA sequences (see subsection 2.5.2). These nucleotides were built
manually in random extended conformations.
The general modelling done in this study adapted a protocol set up by Dr.
Bernd Simon previously described146. All the modelling was done by simulated
annealing using ARIA147 in torsion angle space. During themodelling the parts of
themodel that corresponded to already elucidated structures were kept rigid. The
parts of the RNA that were not included in any of the crystal structures were then
kept free during the modelling. First, the conformation of the free nucleotides of
the RNA was randomized. Then, a standard simulated annealing with the initial
temperature set to 10,000 K followed. Hunchback complex modelling without
distance restraints generated 5055 models in 40,000 MD steps with each step 6 fs
long. Hunchback complexmodellingwith XL/MS data used as distance restraints
was done by generating 4572 models in 120,000 steps with each step 2 fs long. The
distance restraints used were set as 30 Å Cα-Cα upper distance limit with log
harmonic potential.
The generated models were then used to back-calculate their theoretical scater-
ring curves in the same specific conditions used for SAS measurements (see sub-
section 2.5.6) by CRYSOL148 and CRYSON149. These back-calculated curves were
than fitted against the experimental curves. The energy, the distance restraints
energy and the quality of the fit to the SAS experimental data were then used as a
selection criteria to search for the most correct structures.
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(a)
1:0
1:5
(b)
Supplementary Figure 1 The NMR titration of EarP by dTDP-Rhamnose. (a) Overlay of the 15N
HSQC spectra of EarP titrated by dTDP-rhamnose. 15N labelled EarP was as titrated by dTDP-
rhamnose to 1:5 EarP:dTDP-rhamnose molar ratios with steps at 1:0, 1:0.2, 1:1 and 1:3 ratios. Only
the first and the last steps are shown. (b) Chemical Shift Perturbation (CSP) plot of the titration.
The CSP was calculated according to Equation 1.1 for each peak and then plotted against residues
number. The full line indicates the mean, the dashed line the mean plus standard deviation. The
bars in the right portion of the plot without numbering show the unassigned peaks.
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Supplementary Figure 2 Brain tumor-RNA interaction in electrophoretic mobility shift assays
(EMSA). Brain tumor NHL domain (Brat NHL) was incubated with 1 nM radiolabeled NRE2 RNA
at concentrations indicated above the gel for 1 hours at 4◦C. The gel was then resolved on native
6% polyacrylamide gel over 3-4 hours at 4◦C and then storage phosphor screen was exposed to the
gel for 16 hours. The experiments in the second half of the gel contained additional 5 nM PumHD
in the mixture.
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Supplementary Figure 3 The small-angle X-ray and neutron scattering of the Hunchback com-
plex. (a) The small-angle X-ray scattering (SAXS) curve of the Hunchback complex. (b) The
small-angle neutron scattering (SANS) curves of the Hunchback complex. The curves were mea-
sured on complex samples with varying deuteration schemes at different concentrations of D2O
in the buffer. This is indicated in labelling of the curves where B stands for Brat NHL, P stands for
PumHD and N stannds for Nanos ZnF. The preceding number than indicates whether the protein
is protonated (1) or perduetarated (2) and then concentration of D2O in the buffer is stated in %
[v/v]. The samples arefully described in (Table 2.3. (c) The comparison of SANS curves of the four
variously deutared Hunchback complexes measured in 0% D2O buffer. (d) The fits to the SANS
curve of the Hunchback complex with 2H Brat NHL and Nanos ZnF measured in 0% D2O buffer.
The two fits compared are the fit of the back-calculated curve of the Hunchback complex model
which fits this curve the best and the back-calculated curve of the mixture of Pum HD-Nanos
ZnF-RNA complex and Brat NHL-RNA complex in 0.56:0.44 volume fractions. The χ2 values of
the fits are given in the parentheses. (e) The fits to the SANS curve of the Hunchback complex
with 2H Pum HD and Nanos ZnF measured in 0% D2O buffer. The shows analogous fits to (d)
except that the Hunchback complex model is the one which fits this curve the best. (f) The fits to
the SANS curve of the Hunchback complex with 2H Pum HD and Nanos ZnF measured in 65%
D2O buffer. The plot follows the same scheme as in (d) and (e) except that the Hunchback complex
models are the ones which fits this curve the best and the worst.
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Supplementary Figure 4Guinier analysis of the small-angle scattering (SAS) curves. Each panel
shows the fit from Guinier analysis for one experimentally measured scattering curve in the top
panel with the residuals in the bottom panel. All curved were fitted to obey q ×RG < 1.3150.
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Supplementary Figure 5Distance distribution function of selected small-angle scattering (SAS)
curves. Eachplot shows adistance distribution function of one experimentallymeasured scattering
curve.
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Supplementary Figure 6 The distribution of the overall energy of all models of the Hunchback
complex. (a)The total energy of the 5055models calculated during themodelling of theHunchback
complex using only small-angle scattering (SAS) data. The red line shows an energy cutoff above
which the models were discarded. (a) The total energy of the 4572 models calculated during the
modelling of the Hunchback complex using cross-linking/mass spectrometry and SAS data. The
teal line shows an energy cutoff above which the models were discarded.
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Supplementary Figure 7 The cross-linking/mass spectrometry of the Hunchback complex. (a)
The cross-links obtainedusing 1.5mg/mlHunchback complex and 0.2mMDSS. (b)The cross-links
obtained using 1.5 mg/ml Hunchback complex and 1 mMDSS. (c) The cross-links obtained using
0.95 mg/ml Hunchback complex and 0.5 mM DSS. Inter-protein cross-links are in blue, magenta
or green, intra-protein cross-links are in grey. Only cross-links with xQuest score above 25 are
shown. The white stripes in Nanos ZnF indicate the residues undergoing significant chemical shift
perturbation in NMR titration of Nanos ZnF by Brat NHL (Figure 2.8).
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Supplementary Figure 8 The fit of a mixture of Hunchback complex models to the small-angle
X-ray scattering curve. The fits of the representative models of the major and minor ensembles
of models of the Hunchback complex obtained by modelling using the small-angle scattering data
are compared the fit of a mixture of the two models. The fit of the mixture represent 0.52:0.48
major:minor ensemble volume fractions. The χ2 values of the fits are given in the parentheses.
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Supplementary Table 1 The pH against PEG 3350 custom crystallization screen for EarP.
Row
Column
1 2 3 4 5 6
PEG 3350 [% w/v]
A
19 21 23 25 27 29
0.1 M bis-Tris pH 5.5 5.5 5.5 5.5 5.5 5.5
PEG 3350 [% w/v]
B
19 21 23 25 27 29
0.1 M bis-Tris pH 6.0 6.0 6.0 6.0 6.0 6.0
PEG 3350 [% w/v]
C
19 21 23 25 27 29
0.1 M bis-Tris pH 6.5 6.5 6.5 6.5 6.5 6.5
PEG 3350 [% w/v]
D
19 21 23 25 27 29
0.1 M bis-Tris pH 7.0 7.0 7.0 7.0 7.0 7.0
The crystallization screen was done 4◦C with 8 mg/ml EarP in 50 mM Tris, 100 mM NaCl, 1 mM
DTT, 10 mM TDP-Rhamnose, pH 7.6 buffer.
Supplementary Table 2 The pH against PEG 3350 with Amonium Acetate custom crystallization
screen for EarP.
Row
Column
1 2 3 4 5 6
PEG 3350 [% w/v]
A
19 21 23 25 27 29
0.1 M bis-Tris pH 5.5 5.5 5.5 5.5 5.5 5.5
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 3350 [% w/v]
B
19 21 23 25 27 29
0.1 M bis-Tris pH 6.0 6.0 6.0 6.0 6.0 6.0
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 3350 [% w/v]
C
19 21 23 25 27 29
0.1 M bis-Tris pH 6.5 6.5 6.5 6.5 6.5 6.5
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 3350 [% w/v]
D
19 21 23 25 27 29
0.1 M bis-Tris pH 7.0 7.0 7.0 7.0 7.0 7.0
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
The crystallization screen was done 4◦C with 8 mg/ml EarP in 50 mM Tris, 100 mM NaCl, 1 mM
DTT, 10 mM TDP-Rhamnose, pH 7.6 buffer.
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Supplementary Table 3 The pH against PEG 10k with Amonium Acetate custom crystallization
screen for EarP.
Row
Column
1 2 3 4 5 6
PEG 10k [% w/v]
A
11 13 15 17 19 21
0.1 M bis-Tris pH 5.5 5.5 5.5 5.5 5.5 5.5
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 10k [% w/v]
A
11 13 15 17 19 21
0.1 M bis-Tris pH 6.0 6.0 6.0 6.0 6.0 6.0
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 10k [% w/v]
A
11 13 15 17 19 21
0.1 M bis-Tris pH 6.5 6.5 6.5 6.5 6.5 6.5
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
PEG 10k [% w/v]
A
11 13 15 17 19 21
0.1 M bis-Tris pH 7.0 7.0 7.0 7.0 7.0 7.0
Amonium Acetate [M] 0.1 0.1 0.1 0.1 0.1 0.1
The crystallization screen was done 4◦C with 8 mg/ml EarP in 50 mM Tris, 100 mM NaCl, 1 mM
DTT, 10 mM TDP-Rhamnose, pH 7.6 buffer.
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Li, J. Hennig, K. Jung, J. Lassak, and H. G. Hu. Resolving the α-glycosidic linkage
of arginine-rhamnosylated translation elongation factor P triggers generation of
the first ArgRha specific antibody. Chem Sci, 7(12):6995–7001, Dec 2016.
*equal contribution
Contributions
The expression and purification of EarP andEF-P, the in vitro and in vivo activity as-
says and the bacteria hybrid assays were done in the laboratory of Prof Dr. Kirsten
Jung under the supervision of Dr. Jürgen Lassak byDr. RalphKrafczyk and others
as described in previously published works2,55,60. The resonance assigned of EarP
was done with the help of Dr. Janosch Hennig. The resonance assignment of the
EF-P-attached rhamnose was done by Dr. Bernd Simon, who also provided help
with recording the 13C HSQC spectra without decoupling. The crystals structure
of EarP was solved with the help of Dr. Pravin Jagtap.
The cloning, the optimization of expression andpurification, and the resonance
assignment of Nanos ZnF was done by Sophie Winter, M.Sc. as described in the
previously published thesis132. The cloning, the optimization of expression and
purification of BratNHLwas done byDr. Jaelle Foot and the resonance assignment
of Brat NHL was done Dr. Janosch Hennig. The electrophoretic mobility shift
assays were done by Dr. Pawel Masiewicz. Some of the isothermal titration
calorimetry measurements were done by Dr. Vladimir Rybin and Dr. Kathryn
Perez. The mass spectrometry was done by Dr. Mandy Rettel. The crystallization
trails were set up by Dr. Brice Murciano.
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